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Abstract(
 
Notch signaling is an evolutionarily conserved cell-to-cell contact-dependent signaling 
mechanism in multicellular organisms directing cellular fates both in early development and 
adult tissues. In metazoans the Notch pathway consists of multiple paralogs of receptors and 
ligands constituting a complex juxtacrine communications network orchestrating organismal 
homeostasis. Binding of receptors on signal-receiving cells to the ligands on signal-sending cells 
leads to proteolytic cleavage and release of the intracellular domain of Notch (NICD). NICD 
subsequently translocates to the cell nucleus to activate Notch downstream gene expression 
machinery by binding to the Notch-dependent transcriptional regulator CSL. Notch is highly 
context-dependent, and the nature of Notch-mediated outcomes is governed by multiple factors 
such as crosstalk with other signaling pathways, post-translational modifications, and CSL-
binding type preference. Notch is ultimately a cell fate decider with a temporal specificity, where 
context and time can determine whether Notch inhibits or promotes a cellular outcome. The 
importance of the Notch pathway is further emphasized by the dramatic effects of dysregulated 
Notch signaling, which often leads to life-threatening diseases and cancer, such as CADASIL 
and T-ALL.  
 
In this thesis I have glimpsed behind the veil into the unknowns of Notch signaling and 
investigated several novel aspects and peculiarities relating to Notch deregulation in cancer, and 
to Notch regulation via post-translational modifications.  
 
“When Notch and Pim Unite”, Notch1 ICD undergoes post-translational phosphorylation by 
Pim kinases occurring at the nuclear localization signal within the PPD-domain, thus modulating 
the nuclear transport and transactivation of N1ICD. This impacts tumor growth and metabolism 
in breast cancer, and migration in prostate cancer.  
 
In “A Metabolic Turn of Events” we discover that Notch signaling is able to reprogram the 
metabolism in breast cancer where high Notch levels induce the PI3K/Akt pathway leading to a 
shift towards aerobic glycolysis, while low Notch leads to a forced switch to glycolysis following 
mitochondrial oxidative phosphorylation defects. The Notch deficiency subsequently sensitizes 
the cancer cells for low glucose conditions. 
 
Next we unleash “Systematic KOs”, when we knockout CSL in MDA-MB-231 breast cancer 
cells which leads to increased tumor growth and an activated hypoxic response. Furthermore, 
comparison of the Notch wild-type and CSL knock-out transcriptomic signatures reveals an 
upregulation of over 1700 genes not part of the Notch gene signature, suggesting that CSL 
transcriptionally controls a number of genes not part of the canonical Notch signature. 
 
Lastly, we are “Falling Into Hypoxity” as canonical Notch1 is shown to induce HIF2α and 
trigger a HIF1α-to-HIF2α switch in medulloblastoma. However, Notch1 remains tumor 
suppressive in CAM-xenographs and the genetic removal of HIF2α increases tumor growth. 
 
Taken together, this thesis contributes new puzzle pieces to building a complete picture of the 
Notch signaling pathway, its role in cancer, and provides new vistas for future anti-Notch 
therapies.  
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Review(of(the(literature(
Background(
 
All forms of life are complex biochemical systems that propagate themselves in time and space, 
within zones where heat and liquid water can exist. One of these so called habitable zones exists 
in our solar system on our planet Earth. All life, including our own human biochemistry is the 
product of millions of years of evolution, naturally selected to sustain the changes in planetary 
environments. However, the starting point for all life is a small building block called a cell. Cells 
can exist alone or together giving rise to unicellular and multicellular organisms respectively. 
Bacteria are the most simple unicellular organisms consisting of just one prokaryotic cell per 
organism, while humans are multicellular organisms of 10^14 eukaryotic cells per individual. In 
multicellular beings cells come in different shapes and sizes which organize to give rise to tissues 
and organs.  
 
Science is the search for true knowledge, by empirical collection of observations and data from 
our surroundings. It is the fundamental human aspiration to understand and grasp the four or 
more dimensions we are set to exist in. One of the big questions science is trying to decipher is 
the biomechanisms of life, but we humans as a species have only just begun to unravel the 
complex interactions that occur in every cell. As human technology advances, so does our 
knowledge of life.  
 
Introduction(
The(history(of(cancer(
 
Cancer is an ancient menace of multicellular lifeforms. The oldest evidence of cancer comes 
from tumor masses found in fossilized dinosaur bones dating back ~70 million years, as well as 
from the first human cancer victims whose bodies were mummified ~1500 BC. (1). Already 
Hippocrates –“The Father of Medicine” (460 BC – 377 BC) described in his Hippocratic corpus 
with the words “karkinos” and “onkos” (in Greek: crab and mass) the existence and treatment of 
lumps and lesions with both benign and malignant outcomes. During the rise of the Roman 
Empire notably Aulus Cornelius Celsus (25 BC – 50 AD) stressed early diagnosis and 
distinguished inoperable “carcinomas” from resectable “cacoethes”. Arguably the most 
accomplished medical practicioner of antiquity was Galen of Pergamon (129 AD – 216 AD) who 
advanced various scientific disciplines in the footsteps of Hippocrates. Despite promoting 
humorism and the black bile theory of cancer, both Hippocrates and Galen were among the first 
to establish a rational approach to medicine over the prevailing ancient intertwinement of 
medicine and God. After the fall of the Roman civilization, medical practitioners of the 
Byzantine Empire followed the footsteps of Galen and organ specific description of different 
cancers started to take place. 
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During the renaissance the Italian anatomist Gabriele Fallopius (1523 – 1562) described for the 
first time the palpable clinical differences between benign and malignant cancers, still applicable 
today. This was also the first time for the humoristic black bile theory to be challenged and the 
era when modern science started to raise its head with the development of the modern scientific 
method. Shortly thereafter the discovery of microorganisms by Robert Hooke and Antoni Van 
Leeuwenhoek in the middle of the 17th century laid a foundation for microbiology. In the 18th 
century the first correlations between cancer and environmental factors started to emerge, when 
physician John Hill and surgeon Pervical Pott linked cancer to usage of tobacco snuff and to the 
occupation of chimney sweep. In 1859 the release of The Origin of Species by Charles Darwin 
gave humans a glimse of their origins (2). Soon thereafter humanity received its follow-up lesson 
in genetics by Gregor Mendel in the 1860s giving rise to the now well established Mendelian 
genetics (3). 
 
The puzzling nature of cancer remained a mystery from the ancient times all the way to the 19th 
century. During the beginning of the 20th century discovery of antibiotics in 1928  - 1941 by 
Fleming, Chain, and Florey opened up new venues for cancer treatment. Notably actinomycin D 
was used widely to treat pediatric tumors in the 1950-1960s (4). Similarly, in the field of 
nutritional research, folate, or vitamin B9 was synthesized for the first time in 1937, and folate 
antagonists eg. Methotrexate showed unquestionable efficacy in treating children with leukemia 
(5, 6). At the same time, cancer theory was being reformed by progress in bacteriology, 
parasitology, and virology, and microorganisms were falsely labeled as the culprits of all that 
was cancer. This ultimately resulted in a Nobel Prize for Johannes Fibiger in 1926 for his 
discovery of the Spiroptera carcinoma, a worm which he interpreted as being the cause of 
stomach cancer, a hypothesis later proven to be false. However, today several other parasites are 
de facto known to cause cancer. Similarly the paradigm of viruses as causative agents in 
oncogenesis started to expand with the discovery of the Rous sarcoma virus (RSV) (7), and the 
mouse mammary tumor virus (MMTV) (8). With RSV came also the first discoveries of viral 
genome encoded tumor forming oncogenes (v-src), homologues of which were later discovered 
in the avian genome (9). 
 
In the 1930s knowledge of health risks associated with cancer were accumulating, and new tools 
allowed researchers to systematically explore the nature of cancer. As health risks became known 
the US congress enacted the National Cancer Act of 1937, leading to the forming of the National 
Cancer Institute (NCI) in 1939. At the end of World War II the first cancer drug was derived 
from mustard gas widely used in chemical warfare (5). With the discovery of DNA, which paved 
the way into the molecular era of biology, cancer was widely thought of as one unique disease 
with a specific pathophysiological mechanism easily treated once identified. In the early 
seventies, cancer had become the second leading cause of death in the US. This led US president 
Nixon to declare “war” on cancer in 1971 by signing of the National Cancer Act with the aim of 
eradicating cancer as a major cause of death (10). After the start of the national cancer crusade 
many expected quick results, however, to this day, the battle wages on. As it turns out the war 
would not be won in one strike, but in many small skirmishes. 
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Our knowledge of the universe and us as a species is constantly evolving. With the completion of 
The Human Genome Project we now know the sequence of our DNA and can approximate the 
human genome to contain ca. 21000 genes. The ENCODE project currently challenges the 
paradigm of Junk DNA, by suggesting that also this DNA is important. Furthermore, we are also 
currently going beyond genetics in what is termed epigenetics to study inherited traits 
independent of the genetic code; a renaissance of Lamarckism. As basic research methods 
improve so do clinical applications. With the huge advancements in state of the art STED 
nanoscopy by Stefan Hell et al. we are now able to visualize life processes at a molecular scale 
with breathtakingly high resolutions separating objects only a few nanometers apart. With the 
development of improved screening methods for individual mutations and the onset of 
personalized medicine we are that much closer to developing targeted therapies, which like 
homing missiles seek and destroy cancer specifically. Scientific breakthroughs pave the way for 
the modern view on cancer. It is now known that cancer isn’t just one disease, easily triumphed 
by the one right drug, but an umbrella term for a myriad of life-threatening diseases of 
dysregulated cell growth. A scourge of the multicellular.  
 
In the 21st century cancer is viewed as a deregulation of the intertwined cell signaling pathways 
present in each cell in an organism. Modern cancer therapy is based on investigating the 
countless cell signaling components that are involved in mediating cancer formation, ultimately 
allowing us to target specific pathways important in diverse cancer forms. A myriad of cell 
signaling components capable of inducing cancer exist. One of these pathways is Notch. 
 
Historical(background(of(The(Notch(Signaling(Pathway(
 
The first mention of Notch originates from a study on a mutant Drosophila melanogaster strain 
from the 1910s, which was observed by John Smith Dexter working in the laboratory of Thomas 
Hunt Morgan to exhibit notched or beaded wings in a partial loss of function phenotype (11-14). 
Later, in the beginning of the 1940s, Donald F. Poulson kicked off the Notch field in D. 
melanogaster by observing and documenting for the first time the embryonic lethality in 
homozygous null Notch mutants (15, 16). Notch was cloned in the mid 1980s independently by 
two research groups, i.e. by Artavanis-Tsakonas’ and Michael Young’s group thus reinvigorating 
the Notch field in metazoans (17-20). At the same time light was shed on the protein itself as 
Notch was identified to be a trans-membrane receptor (21). The identity of two ligands, namely 
Delta and Serrate were soon to follow (22-24). 
Following the initial discovery of the Notch gene, dramatic effects on the pathways deregulation 
started to surface. At the eve of the 1990s, a chromosomal translocation giving rise to a truncated 
form of the mammalian Notch receptor was identified in <1% of patients with T-cell acute 
lymphoblastic leukemia (T-ALL) (25). The subsequently named translocation-associated Notch 
homolog (TAN1) was able to, when ectopically expressed in bone marrow, to develop T-cell 
neoplasms (26). Yet, the effect of Notch on the development of T-ALL seemed at the time small 
and insignificant. However, years later the field experienced a paradigm shift when Andrew P. 
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Weng together with Jon C. Aster discovered that over 50% of T-ALL cancers harbor activating 
mutations in the Notch1 receptor!(27). 
 
At the end of the 1980s evidence of a role for Notch in breast cancer was also accumulating. The 
identification of the integration site for the mouse mammary tumor virus (MMTV) led to the 
discovery of another truncated Notch paralog, named INT3 (integration site 3), later to be known 
as Notch4 (28). Similarly, overexpressing Notch4 in mammary tissue of transgenic mice led to 
the development of mammary tumors in 100% of the cases (29).  
 
Today we know that Notch is involved in a significant number of processes both in development 
and adult tissue homeostasis (30-32). The development of the Notch pathway is thought to 
stretch hundreds of millions of years into the past, being associated with the rise of the metazoan 
multicellular organisms (33, 34). At the eve of transition from unicellularity to multicellularity, 
the fundamental units of life, namely the cells needed to develop means for communication, 
coordination, and organization between each other. These functions were mediated by signal-
transduction pathways, which allowed cells to orchestrate differentiation programs for 
development of specialized cells and organs. In metazoans, less than 20 different pathways 
developed to mediate developmental processes but out of these only 7 form the “crème de la 
crème”, controlling most of the cell communication that occurs during development (33, 35). The 
seven major cell-cell signaling pathways are: Wnt; Transforming Growth Factor β (TGF-β); 
Hedgehog; Receptor Tyrosine Kinase (RTK); Jak/STAT; nuclear hormone receptor; and Notch 
(30). 
Notch is indeed one of the “heavy-hitters” in metazoan developmental, as well as in postnatal 
signaling, regulating multiple processes which include: proliferation, apoptosis, cell polarity and 
more, giving rise to tissue-broad regulation such as lateral inhibition and induction, stem cell 
maintenance, patterning, and binary cell fate decisions (30, 36). Inhibition and induction of 
differentiation, as well as lineage specification at different branch points in development display 
the context-dependent signature function of Notch. In one context, precursors of equipotency can 
be steered towards differential cell fates upon receiving unequal levels of Notch signal, while in 
another context Notch can simply induce terminal differentiation (37). Furthermore, Notch has 
recently been described as an inducer of transdifferentiation during adult tissue homeostasis, 
where in the adult lung Notch levels can lead to direct conversion of cellular fates from mucus 
secreting club and goblet cells, to mucus-transporting ciliated cells, and vice versa (38), thus 
further expanding the reach of the Notch pathway. All these functions continue to have relevance 
in self-renewing tissues of the adult vertebrate organisms but also in tumorigenesis.  
 !!!!
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Developmental(processes(involving(Notch(signaling(
 
Lateral(Inhibition(
 
The most classical developmental process controlled by Notch is lateral inhibition during 
neuronal development. Starting with a cell population with a random expression pattern of Notch 
ligands and receptors, the cells will slowly undergo a change towards a ‘checkers’ or ‘salt-and-
pepper’ -pattern, where cells that end up only expressing Notch will remain undifferentiated and 
later commit to a epithelial fate, while cells with Jagged-ligand expression will differentiate to 
form neurons. This allows for neurons to develop intertwined in supportive glial cells. Thus, 
Notch signaling allows a full spectrum of cells to develop, separating early-born cell types from 
late-born cell types. 
 
The classical view of lateral inhibition suggests that in neurons expression of the Notch ligand 
Dll1 is induced by the proneural genes Mash1 and Ngn2. The ligands then bind to Notch 
expressed on neighboring cells and via subsequent release of NICD activate the Notch 
downstream gene reponse in these cells. The NICD-RBPjκ complex in turn induces the 
expression of Hes1 and Hes5, which suppress the proneural genes and subsequently the Notch 
ligand genes. The modern view of lateral-inhibition on the other hand suggests the Ngn2-Dll1-
Hes1 axis oscillates dynamically in neural progenitors, in a manner optimizing neural progenitor 
cell proliferation and neuronal differentiation (39). Moreover, the developing nervous system is 
partitioned into many compartments by boundaries, where compartment cells may oscillate Hes1 
while boundary cells express Hes1 in a sustained manner giving rise to neuron-free zones (40). 
Sustained or oscillatory Hes1 expression patterns may thus also contribute to differential 
characteristics in undifferentiated neural progenitor cells (39). Furthermore, the dualistic nature 
of Notch also aids the plasticity in the adult brain, where Notch helps maintain stem cells and 
transit-amplifying (TA) cells, whereas inhibition of Notch leads to an increase in TA cells and 
neurons (41, 42). 
 
Binary(cell(fate(decisions(
 
Another well-defined developmental mechanism involving Notch is that of asymmetric cell 
division which can give rise to sibling cells of distinct fates and characteristics. Asymmetric 
daughter fates can be determined by asymmetrically distributed cell fate determinants, which 
segregate to only one of the two daughter cells (43). Fate determinants, such as Numb and 
Sanpodo, which interact with Notch, can through their asymmetric distribution also affect the 
distribution of Notch (see section on Numb and Sanpodo). While Numb antagonizes Notch levels 
and vice versa, Sanpodo potentiates the effects of either low Notch or high Notch in the two 
different settings (44). 
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Lateral(induction(
 
Lateral induction represents the third mode of Notch action in development, where Notch and 
ligand expression on adjacent cells results in positive feedback which elevates expression of both 
Notch and ligand on both cells (45). Thus, instead of inhibiting each other, the cells cooperate to 
meet their fates together (46). For example the formation of terminally differentiated secondary 
lens fibers from the monolayer of epithelial cells on the lens surface in the vertebrate ocular lens, 
relies on FGF-mediated switching from lateral inhibition to lateral induction (47). Another 
example involves the formation of arteries, specifically the smooth muscle cell (SMC)–layers 
surrounding the endothelial vessel lumen. Expression of Jagged on endothelial cells induces 
Notch and subsequently Jagged on the first SMC-layer, an effect which propagates via lateral 
induction to the following SMC layer (48). Similar lateral induction has also been described in 
the development of the inner ear(49, 50). 
Molecular(basis(of(The(Notch(Pathway(
 
The(Notch(
 
In the bilaterian metazoans of the animalian kingdom the Notch pathway of juxtacrine signaling 
varies in complexity depending on the species and whether they are invertebrates or vertebrates. 
Classic canonical Notch signaling is mediated via DSL (Delta, Serrate, Lag-2) ligand binding to 
the Notch receptors, which leads to cleavage of the receptor and release of the Notch intracellular 
domain (NICD). NICD subsequently translocates to the cell nucleus binding to the transcriptional 
regulator CSL (CBF-1 in humans, suppressor of hairless in Drosophila melanogaster, LAG-1 in 
Caenorhabditis elegans) thus activating Notch target gene expression. Much of the core 
mechanistic knowledge of Notch today comes from genetic studies in C. elegans and D. 
melanogaster. In C. elegans the Notch-related receptors LIN-12 and GLP-1 are activated by 
binding to the ligands LAG-2, APX-1, ARG-1, and DSL-1 while downstream Notch signaling is 
mediated via the transcriptional regulator LAG-1 (51). Likewise in D. melanogaster, a single 
Notch receptor is activated by two different ligands, namely Serrate and Delta, and where NICD 
ultimately binds suppressor of hairless (52, 53). Despite differences in nomenclature, the core 
units exhibit conserved functionality among species. The desired goal of course is to understand 
the functionality of Notch in Homo sapiens, i.e. humans. 
 
In humans, the Notch pathway involves 4 receptors (Notch1-4), with the encoding genes on 
chromosomes 9, 1, 19, and 6 respectively (54-56), as well as ligands (Jagged1&2, Dll1,3,4) on 
chromosomes 20, 14, 6, 19, and 15 respectively (57-61). Both receptors and ligands exhibit 
redundant overlapping functions as well as distinct properties. A classic canonical Notch 
signaling cascade starts with two neighboring cells making physical contact with each other. This 
allows receptors on the plasma membrane of the signal-receiving cell to bind DSL ligands 
expressed on the signal-sending cell. Of course in reality, all cells are both signal-sending and 
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signal-receiving to different degrees, yielding bidirectional signaling complexity. A mechanical 
“tug of war” follows which subsequently leads to the endocytosis of the ligand and cleavage of 
the receptor. The Notch receptor has 3 cleavage sites, S1 is an early cleavage event catalyzed by 
Furin convertases occurring in the trans-Golgi apparatus allowing for heterodimerization and 
correct assembly of the receptor (62). After assembly the signal-sensitive receptor is transported 
to the plasma membrane in wait for activation. S2 cleavage is the first activating event which is 
characterized by the formation of a truncated Val1721 receptor. S2 cleavage is catalyzed by 
ADAM (A Disintegrin And Metalloproteinase) family metalloproteases, notably by ADAM-17 
and ADAM-10. The third cleavage event at S3/S4 is mediated by gamma-secretase and leads to 
the release of the 1744Val N-terminal intracellular domain of Notch (NICD). Also other 
cleavages occur, but the 1744 cleavage generates the most active and stable form of NICD (63). 
Following cleavage at S3, NICD subsequently translocates to the nucleus where it binds CSL to 
activate gene expression. 
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Figure 1.The canonical Notch signaling pathway. The Notch receptor is translated in the ER 
and undergoes cleavage at S1 by Furin convertase and subsequent heterodimerization in the 
Golgi apparatus. From the Golgi, the mature Notch receptor is transported to the plasma 
membrane. At the membrane, the active Notch1 receptor can bind a Notch ligand (Jagged1) 
presented by a neighboring cell. This leads to endocytosis of the ligand-receptor complex, which 
reveals S2 for cleavage by ADAM metalloproteases. This event subsequently reveals S3 for 
cleavage by the gamma-secretase complex, and releases NICD. NICD then translocates to the 
nucleus and binds CSL-MAML in a complex, displacing the corepressors (Co-R) and instead 
recruits coactivators (Co-A) for initiation of Notch downstream gene expression.  
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The(domains(of(the(Notch(receptor(
 
Notch receptors are type I transmembrane glycoproteins out of which the prototypical 
Drosophila Notch weighs around 300kDa. The receptors are synthesized as precursor proteins 
and proteolytically cleaved in the trans-Golgi complex by a furin-like convertase at S1 (62, 64), 
followed by a non-covalent heterodimerization of the extracellular 180kDa portion to the 120kDa 
transmembrane and intracellular component of Notch (62). After processing in the Golgi and the 
endoplasmid reticulum (ER), which includes both glycosylation and fucosylation of several EGF 
repeats (65)!(66, 67), the mature receptors are transported to the plasma membrane. Extracellular 
binding between Notch ligands and receptors is mediated via the calcium-dependent EGF 
(epidermal growth factor-like) repeats (68, 69). Mammalian Notch1 and Notch2 proteins contain 
36 tandemly arranged EGF-repeats, while Notch3 and Notch4 have 34 and 29, respectively (70). 
Out of these, EGF-repeats 11-12 are most important for productive interactions with ligands (71, 
72). The ligand-binding extracellular portion of Notch is attached to the NRR which maintains 
metalloprotease resistance in the absence of ligand binding. The importance of this regulation is 
demonstrated by the fact that most point mutations and insertions that lead to constitutive 
activation of Notch1 in T-ALL are found within the NRR. (27) The NRR consists of three 
cysteine-rich LIN-12-Notch repeats (LNR) and the heterodimerization domain (HD) containing 
both the S1 (furin) and S2 (metalloprotease) cleavage sites both preceding the transmembrane 
portion (73). The LNR, together with the HD domain, cover the S2 metalloprotease site in the 
autoinhibited state. Following ligand association and endocytosis a pulling force is exerted on the 
receptor which according to the mechanotransduction model of Notch activation leads to 
stripping of the LNR off of the S2 site, revealing it for proteolytic processing by 
Kuzbanian/ADAM10 and ADAM17/TACE (tumor necrosis factor α converting enzyme) (74)!
(75). An alternative hypothesis for the mechanotransductive regulation of S2 cleavage exists and 
is called the allosteric model where allosteric regulation of Notch yields a reconfiguration of the 
molecule subsequently allowing ADAMs to cleave at S2. The S2 cleavage creates the 
membrane-tethered Notch extracellular truncation (NEXT), which is a substrate for γ-secretase 
that progressively cleaves NEXT within the transmembrane domain from the intramembrane 
layer towards the middle of the transmembrane domain, from site S3 to S4. Cleavage at S3 is 
sufficient to release NICD, while the subsequent cleavage at S4 releases the transmembrane Nβ 
peptide. Different NICD species can be formed at S3 cleavage, however, the most active and 
stable one is the NICD cleaved at valine 1744 (63, 74). The γ-secretase enzyme complex consists 
of four membrane proteins, namely the catalytic component Presenilin and three cofactors: 
Nicastrin, Pen2 and Aph1, in a 1:1:1:1 stoichiometry (76). Mammalian cells exhibit at least two 
presenilin (PS1/2) and two Aph isoforms, potentially allowing for at least four different γ-
secretase complexes to form, and especially the PS1/2 switch can contribute differentially to 
Notch signaling (74, 77, 78). Furthermore, the enzyme complex can be reduced to the functional 
trimeric core of PS1/Pen2/Aph1 and still remain 50% active, yet nicastrin is required for optimal 
stability and activity (79).   
 
!!
!
Review(of(the(literature(
!
! !
16!
The active Notch fragment NICD translocates to the nucleus with the help of nuclear localization 
sequences. Previous research has indicated that NICD contains two nuclear localization sequence 
domains (NLS1-2), located N-terminally and C-terminally of the ANK repeats, respectively (80), 
although up to four distinct potential nuclear localization sequences have been observed (81). 
The N-terminal NLS1 contains 2 basic monopartite sequences for nuclear localization at 1779-
1783, and 1820-1825, while the C-terminal NLS2 has two closely spaced sequences of basic 
amino acids at 2156-2160 and 2177-2182 previously thought to function together as a bipartite 
NLS (82) after mutational removal of the two clusters of basic amino acids and the linker region. 
However, the two basic sequences have later via mutational studies been shown to not mediate 
nuclear localization (81). Classical nuclear localization sequences (cNLS) are recognized by 
Importin-α which via its 2 binding pockets; the minor and major groove can bind a monopartite 
NLS singly or the two clusters of a bipartite sequence, normally separated by a 9-12 amino acid 
linker (83). Recent findings however show the existence of longer linker sequences with 
functionality in either direct binding to the Importin-α backbone or in regulating binding affinity 
to Importin-α (83). Post-translational modification of the linker sequence or sequences close to 
the bipartite NLS may also directly affect the conformation needed for the bipartite NLS binding 
to the minor and major groove (83-85). Nuclear transport of Notch has been shown to be 
mediated by Importin-α (81). 
 
Binding of NICD to CSL occurs mechanistically via a bipartite functional entity termed 
RAMANK and is constituted by the stable high-affinity interaction of RAM (86, 87) and weak 
interaction of the seven ankyrin repeats (ANK) domain to CSL (82). The N-terminal RAM 
domain of NICD binds via its short (≤25 residues) ΦWΦP motif to the BTD pocket of CSL, and 
substitutions in this motif significantly reduces binding affinity (86-89). While the RAM domain 
mediates docking to CSL the ANK repeat domain is alone capable of mediating transactivation 
of CSL via weak interactions (82). Formation of the ternary complex of CSL-NICD-MAML is 
however ANK-dependent and occurs independently of RAM (88, 90). Neither NICD nor CSL 
alone is able to bind MAML, however when complexed together the two proteins cooperate in 
binding MAML with high affinity, suggesting that the function of the NICD-CSL complex and 
ANK repeat domain is to allow MAML association (73). MAML is the essential cofactor 
required for initiation of the Notch downstream response, and the CSL-NICD-MAML complex 
subsequently recruits the p300 histone acetyltransferase for activation of transcriptional 
responses (91). 
 
Structurally CSL contains a 420 amino acid core encompassing the N-terminal domain (NTD), 
the β-trefoil domain (BTD) and the C-terminal domain (CTD) (86), and binds DNA as a 
monomer with the NTD and BTD at the core consensus site (C/A/T)(G/A)TG(G/A/T)GAA (92). 
Also other weaker consensus sites exist (93). Interestingly, increased complexity is added to the 
system by the fact that several Notch responsive genes, including Hes and Hey related genes 
have dual CSL binding sites, and sequence paired sites (SPS) which can be arranged either in a 
head-to-head or head-to-tail configuration (93-95). Different CSL configurations favor different 
NICDs, for example N1ICD prefers paired sites while N3ICD performs best on single sites (94, 
96). 
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CSL is considered to function in the absence of NICD as a repressor of its target genes with the 
help of a myriad of corepressors such as CIR, FLH1C/KyoT2, SPEN aka. SHARP/MINT, 
histone demethylase Lid/KDM5A, and NCoR/SMRT (97-99) that can form several different 
corepressor (CoR) complexes with different binding modalities. For example, KyoT2 binds with 
high affinity to CSL via the BTD with a similar ΦWΦP motif as found in the RAM domain of 
NICD (100), while binding studies with SHARP/MINT, which is emerging as the most critical 
Notch corepressor in vivo, suggests different mechanisms of interaction (99, 101, 102). CoR 
complexes are further able to recruit histone deacetylases (HDACs) and histone methylases to 
modulate the chromatin environment. At the event of NICD, MAML and other coactivators such 
as histone acetyltransferase  (HAT) complexes p300/CBP and p300/CBP-associated factor 
(PCAF) are recruited to displace corepressors, and activate target gene expression. This dual 
mode of action allows for tight control of Notch downstream genes. The view of CSL as a static 
repressor in the absence of NICD is however being challenged by data indicating that CSL may 
be dynamically recruited to DNA-binding sites in response to Notch activation (103). 
Alternatively preloaded complexes may be exchanged. 
 
Following NLS2 is the evolutionary divergent transactivation domain (TAD) which in murine 
Notch1 is located at amino acids 2194-2398 and is capable of Notch paralog-dependent 
autonomous transactivation of CSL (104, 105). The nuclear protein EBNA2 encoded by the 
Ebstein-Barr virus also possesses a similar but distinct TAD domain capable of CSL 
transactivation (104). A complete TAD domain can only be found in Notch1 and Notch2, and out 
of the two Notch1 exhibits stronger activity. (104, 106). Notch3 possesses a shorther and much 
weaker TAD requiring a zinc-finger binding site near the CSL site for functionality (94), which 
partially explains the weaker transactivation seen by N3ICD compared to N1ICD and N2ICD 
(106, 107). N4ICD completely lacks a TAD (108). The TAD domain also contains a C-terminal 
PEST motif rich in proline (P), glutamic acid (E) serine (S), and threonine (T), which via post-
translational modifications controls half-life and degradation of NICD (30).  
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Figure 2. The domains of the mammalian Notch receptors and ligands. Notch receptors and 
ligands are divided into extracellular and intracellular domains (ECD and ICD respectively). The 
Notch ECD contains 29-36 tandemly arranged epidermal growth factor like repeats (EGF), and a 
negative regulatory region (NRR) containing the LIN-12-Notch repeats (LNR), and the 
heterodimerization domain (HD), which encompasses the S2 cleavage site. The S3 cleavage site 
is located immediately after the transmembrane domain (TM). The Notch ICD consists of the 
RBP-J associated molecule (RAM) domain, two nuclear localizations sequences (NLS), 7 
ankyrin repeats (ANK), a transactivation domain (TAD), and a proline, glutamic acid, serine, and 
threonine-rich domain (PEST). Note the exceptions in Notch3 and Notch4, where Notch3 
exhibits a smaller TAD domain, while Notch4 is lacking the TAD and the second NLS. The 
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Notch ligands contain on their ECD the MNNL (Module at the N-terminus of Notch ligands) 
module, DSL (Delta/Serrate/LAG-2) motif, and DOS (Delta and OSM-11-like proteins) domain, 
which participate in ligand binding. The Jagged ligands also contain a cysteine-rich area close to 
the transmembrane domain. At the ICD, Jagged1, Dll1/4 also contain a PDZ (post synaptic 
density protein [PSD95], Drosophila disc large tumor suppressor [Dlg1], and zonula occludens-1 
protein [zo-1]-binding motif, which participates in intracellular protein-protein binding.  
 
Notch(ligands(
 
The Notch ligands are also type I transmembrane proteins with a similar architecture as the 
receptors containing an extracellular domain (ECD), a singular transmembrane domain, and an 
intracellular domain (109). The ECD of the ligands contains an N-terminal MNNL (Module at 
the N-terminus of Notch ligands) module, a DSL (Delta/Serrate/LAG-2) motif, and may also 
contain a specialized tandem EGF-repeat called the DOS (Delta and OSM-11-like proteins) 
domain, as well as several other tandem EGF-repeats (109). The MNNL, DSL and DOS domains 
are all involved in receptor binding (73, 74). Recently, the MNNL has also been described to 
contain a C2-domain which through calcium loading can bind different phospholipid moieties 
(110). The canonical DSL ligands Jagged1, Jagged2 and Dll1, Dll3, and Dll4 in mammals 
correspond to the Serrate and Delta ligands in Drosophila respectively. The mammalian Notch 
ligands have so far been documented to have overlapping functional redundancy with the 
exception of Dll3. Dll3 is the most divergent of the ligands with inability to efficiently localize to 
the plasma membrane and to signal in trans, and has subsequently been hypothesized to act as an 
inhibitor of ligand-induced Notch signaling (30, 111-113). What separates the Jagged from the 
Dll ligands is the cysteine-rich motif close to the plasma membrane found only in Jagged ligands. 
The ICD of Jagged1, Dll1/4 contains a PDZ (post synaptic density protein [PSD95], Drosophila 
disc large tumor suppressor [Dlg1], and zonula occludens-1 protein [zo-1]-binding motif, which 
has been suggested to have a role in allowing binding of PDZ-binding domain containing 
proteins (114), and subsequent bidirectional signaling (115). 
 
Downstream(effectors(
 
A large number of Notch downstream target genes have been identified, and the best 
characterized ones are the transcriptional repressors of the basic helix-loop-helix (bHLH ) type of 
transcriptional repressors. These include the Hes (Hes1-7) and Hey families (Hey1, Hey2, HeyL, 
HesL/HeIT, Dec1/BHLHB2, Dec2/BHLHB3) (116-118). Hes1 acts as a tumor suppressor in 
epithelial cells by inhibiting proliferation, while being in turn downregulated by 17β-estradiol in 
ER-positive breast cancer thus increasing proliferation (119). Other well-characterized Notch 
downstream targets are c-myc, nuclear-factor-kappa (NF-κB), vascular endothelial growth factor 
(VEGF), p21, p27, Akt, Slug, and Snail (120-123). Notch1 also controls the expression of 
Notch3 (124), and is involved in regulating the cell cycle by induction cyclin D1 and CDK2 
thereby promoting S1 entry (125). With the development of more and more powerful RNA-
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sequencing techniques (126), detailed information about the various Notch-transcriptomes is 
emerging. The immediate Notch response is considerably larger and more diverse than 
previously thought with the appearance of distinct cell-type and tissue specific sets of only 
partially overlapping transcriptomes (30). Furthermore, Notch-dependent long non-coding RNA 
expression profiles have also been unraveled (127). 
 
PostEtranslational(modifications(of(Notch(
 
Post-translational regulation of Notch is an emerging field of research with the potential to 
further elucidate the pathway’s context-dependent pleiotropism. Several of the domains of NICD 
are targeted by different enzymes to modulate the outcome of NICD.  
 
Phosphorylation(
 
Protein phosphorylation is one of the most important regulatory mechanisms in eukaryotic cells, 
and it is estimated that one third of all eukaryotic proteins undergo reversible phosphorylation 
(128). Indeed, Notch is included in the phospho-protein family and contains multiple paralog-
specific phosphorylation sites with different regulatory functions (120). 
Glycogen synthase kinase-3β (GSK-3β/Shaggy) is able to phosphorylate N2ICD at several 
residues C-terminally of the ANK domain thus negatively regulating its transcriptional activity 
(129). However, GSK-3β in turn enhances the stability of N1ICD and is required for Hes-1 
expression (130). Granulocyte colony-stimulating factor (G-CSF) can phosphorylate N2ICD at 
multiple sites, including S2078, thus inactivating the molecule (131). Cyclin-dependent kinase 8 
(CDK8) interacts directly with MAML and phosphorylates N1ICD at multiple residues in the 
PEST domain thus strongly enhancing the PEST-dependent degradation of N1ICD by 
Fbw7/Sel10 ubiquitin ligase (132). Nemo like kinase (NLK) is able to phosphorylate N1ICD C-
terminally of the ANK domain between amino acids 2126-2282 decreasing transcriptional 
activity by interfering with formation of Notch ternary complex (133). On the other hand N3ICD 
activity is increased by NLK phosphorylation (133). PKC zeta phosphorylates membrane bound 
NEXT and full length Notch receptors, and depending on activation state, either enhances NICD 
formation or triggers Notch receptor recycling (134). More recently, Notch4 has been observed 
to be targeted for Akt phosphorylation, and subsequent 14-3-3 association thus restricting nuclear 
translocation of N4ICD (135). 
 
Ubiquitination(
 
Various components of the Notch signaling pathway, including both receptors and ligands, are 
modified by E3 ubiquiting ligases (136). The prototypical E3 Notch modulator F-box and WD-
40 (Fbxw7/Sel10/cdc4) ubiquitinates NICD at CDK8 phosphorylated sites within the PEST 
domain thus regulating its half-life via ubiquitin-proteasome-mediated degradation (132, 137-
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139). Even higher levels of control over degradation exist, for example serum- and 
glucocorticoid-inducible kinase 1 (SGK1) phosphorylation of Fbxw7 at serine 227 functions as a 
switch to allow Fbxw7 to ubiquitinate N1ICD (140). The significance of regulating NICD half-
life is underlined by the fact that both activating gain of function mutations of NOTCH1, as well 
as loss-of-function mutations of FBXW7 can be found in T-ALL (141, 142). Over 50% of T-
ALL cases harbor activating NOTCH1 mutations within the HD domain and/or the PEST motif 
(27), while a high percentage of FBXW7 mutations further amplifies NICD lifetime in the cells 
and mediates γ-secretase resistance (142, 143). Activating NOTCH1 mutations together with the 
loss of NUMB, a negative regulator of Notch, have also been observed in non-small-cell lung 
cancer (144). Another E3 ubiquitin ligase affecting Notch is Deltex which by direct association 
to NICD via the ANK domain (145), as well as via the β-arrestin protein Kurtz, which leads to 
ubiquitination of NICD, positively regulates Notch(146). Deltex is thought to direct endosomal 
trafficking of Notch leading to both positive and negative outcomes in regards to NICD 
formation (147, 148). Also other non-E3 ubiquitin ligases exist which can associate with NICD 
and affect Notch signaling (30). 
 
Hydroxylation(
 
The HIF asparaginyl hydroxylase, factor inhibiting HIF1α (FIH) is able to hydroxylate HIF1α, 
and also N1-3ICD, but not N4ICD (149, 150). The identified hydroxylation sites on N1ICD are 
found at N1945 and N2012, located within the ANK repeats domain, and FIH hydroxylation 
seems to affect Notch signaling diversity (30, 149, 150).  
 
Acetylation(
 
Acetylation of Notch has also been implicated in NICD stability and subsequently in Notch 
downstream gene expression. Recently 14 acetylation sites targeted by PCAF and p300 were 
identified on N1ICD prolonging N1ICD half-life, while the deacetylase SIRT1 was shown to 
oppose this stabilization (151). 
On the other hand, N3ICD undergoes N-terminal acetylations and deacetylations at K1692 and 
K1731, within the RAM domain, by p300 and HDAC1 respectively (152). Acetylation primes 
N3ICD for subsequent ubiquitination and proteasomal degradation, thus also affecting the 
transcriptional activity of the protein (152). 
 
Other(modifications(and(regulators(of(Notch(receptors(and(ligands(
 
Glycosylation(
 
Post processing after S1 cleavage in the trans-Golgi network leads to addition of both O-linked 
fucose and O-linked glucose to the EGF-repeats of the Notch extracellular domain (NECD) by 
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Protein O-fucosyltransferase (POFUT1/Ofut1) and Protein O-glucosyltransferase 
(POGLUT1/Rumi), respectively (65, 67). Two new forms of NECD glycosylation called O-
GlcNac’ylation and O-Xylosylation by Rumi have also recently been discovered in Drosophila 
(153, 154). O-fucosylation is believed to support correct functioning of all Notch paralogs, while 
the O-fucose modified EGF-repeats can further be elongated by the Fringe family of 
glycosyltransferases by addition of N-acetylglucoseamine to O-fucose (66, 67) to modulate 
Notch signaling activity (155). In Drosophila, Fringe increases Notch sensitivity to Delta while 
decreasing sensitivity to Serrate by addition of GlcNac to O-fucose (155, 156). Three Fringe 
homologs exist in mammals, namely Lunatic Fringe, Manic Fringe, and Radical Fringe (157, 
158). Distinct functions for all three Fringes have been observed in a wide variety of contexts in 
mammalian cells, however, the overall significance of Fringe modulation is still largely unknown 
(159). 
 
Numb(&(Sanpodo(
 
Numb is a membrane associated protein whose expression inversely correlates with that of 
Notch, and Numb thus functions as a negative regulator of Notch output. For example during 
sensory organ development, in the sensory organ precursor cells (SOP) in Drosophila, Numb 
localizes along the anterior-posterior axis of the fly yielding an asymmetric cell division of pI 
cells, thus generating characteristically distinct pIIa (Notch ON) and pIIb (Notch OFF) cells 
(160-162). Numb antagonizes Notch by binding Notch in complex with Sanpodo, as well as the 
endosomal protein α-adaptin, which is required in cells supporting high levels of clathrin-
mediated endocytosis (163-166). Sanpodo is a four-pass transmembrane protein discovered in 
Drosophila, which potentiates the effects of Numb during asymmetric cell division. In pIIa cells 
Sanpodo binds Presenilin, a part of the γ-secretase complex, while in pIIb cells Sanpodo 
mediates internalization of the Notch receptor (167). Numb induces the endocytosis of Sanpodo 
(168), and is specifically found localized in endosomes controlling endosomal trafficking and 
recycling of Notch/Sanpodo complexes (169). Numb is thus believed to inhibit Notch/Sanpodo 
complex recycling to the membrane, instead stalling the internalized endosomes in the cytosol 
(169). 
 
Mammalian homologues of Numb have been observed to recruit ubiquitination machinery 
directly to the plasma membrane thereby promoting ubiquitination of the Notch receptor and 
subsequent degradation of NICD (170). Numb has also been observed to disrupt the formation of 
the murine double minute 2 (MDM2) and p53 complex, thus protecting p53 from degradation, 
subsequently leading to inhibited Notch activity (171, 172). Numb governs the endocytic 
trafficking of the Notch1 receptor, either yielding recycling back to the cell membrane or 
degradation in lysosomes (173). Overall, several isoforms of mammalian Numb with arguably 
redundant functions have been identified, and are believed to govern not only asymmetric cell 
division in the CNS, but the proper development outside the CNS as well (162).  
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NonEcanonical(Notch(
 
Non-canonical Notch signaling is an umbrella term to describe CSL-independent Notch 
activation and downstream signaling through other pathways than the classical Notch target 
genes (174). The first reports of non-canonical Notch signaling came already during the 1990s 
when Notch was found to inhibit muscle cell differentiation independently of CSL (175, 176). 
Questions that still baffle the non-canonical Notch field is how non-canonicity is mediated by 
transcription factors other than CSL (177, 178), and how it is mediated by interactions that occur 
in the cytoplasm (174). According to a recent review by Ayaz & Osborne 2014, non-canonical 
Notch can be divided into three logical categories, namely: 1) γ-secretase mediated activation of 
Notch occurring independently of ligand interaction, 2) NICD activity independent of CSL, and 
3) membrane bound Notch signaling in the absence of γ-secretase cleavage, sometimes also 
without ligand activation (179). One example of physiological non-canonical Notch signaling 
comes from Drosophila and mammalian neural stem cells where PTEN-induced kinase 1 
(PINK1) has been shown to recruit full-length Notch to the mitochondria (180). 
 
A prime example of when canonical and non-canonical Notch signaling unite is during the 
crosstalk with Wnt signaling, an event with both synergistic and antagonistic effects and the 
potential to orchestrate the outcome of many developmental fates (181, 182). Notch and Wnt 
have been shown to converge synergistically when β-catenin interacts with canonical Notch 
bound to CSL in induction of arterial fate in vascular progenitors (183). Similar synergy is also 
reported in tumorigenesis and proliferation of intestinal cells (184), as well as in maintenance of 
hematopoietic stem cells (185). By contrast, ligand/CSL-independent Notch i.e. non-canonical 
Notch signaling, is often reported to antagonize Wnt/β-catenin (174). For example, in 
Drosophila, Notch downregulates armadillo/β-catenin independently of transcriptional activity 
(186). Also Numb has been hypothesized to have a role in the crosstalk with both Notch and Wnt 
(174).  
Notch(receptor(and(ligand(trafficking(
 
Endocytosis and recycling of Notch receptors and ligands in both signal-sending and signal-
receiving cells has been observed to be critical for directing and regulating Notch activity. 
Trafficking and recycling of Notch receptors is observed as a constitutively occurring event in 
cells, where numerous regulators of endocytic trafficking have in the past 15 years been 
identified as being essential for activation of Notch signaling (187, 188). Numb is a known 
regulator of Notch1 trafficking which when active will redirect receptors from recycling to 
lysosomal degradation (173). Regulation of Notch receptor trafficking is also important during 
cleavage of NICD at S3 as this is thought to occur both at the plasma membrane and in 
endosomes as they transition to become lysosomes. 
 
Ligand endocytosis and recycling is a poorly understood process, however, ligand internalization 
is believed to be induced by monoubiquitination of the ligands by the E3 ubiquitin ligases 
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Neuralized and Mindbomb (74). Current models suggest that the subsequent recycling of the 
ligand produces a more active cell surface ligand, however, exact modifications occurring during 
this event are still under debate. Suggested modifications include: post-translational 
modification, clustering of ligands, and localization into specific plasma membrane 
microdomains (189, 190).  
 
Notch(signaling(in(disease(
 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL) is a progressive central nervous system degenerative disorder linked to Notch3 
mutations (191), causing mainly vascular defects. Onset of the disease is highly variable, and 
clinical presentations vary from patient to patient but include: Migraines with aura, transient 
ischaemic attacks, dementia, apathy, and mood changes (192). Furthermore, 
leukoencephalopathy showing white matter pathology is observed on MRI, and CADASIL leads 
to a bedridden terminal stage within a mean of 25 years (192).  First identified in 1977 by two 
different groups (193, 194) and later mapped to chromosome 19 (195), CADASIL is now known 
to be caused by over 70 different mutations in the extracellular domain of Notch3 (196, 197), 
leading to odd numbers of cysteine residues causing impaired formation of cysteine disulfide-
bridges in the EGF-repeats domain (191). However, the exact molecular mechanisms behind 
CADASIL remain still largely unknown. 
 
Alagille syndrome is a multisystem developmental disorder caused by Notch signaling pathway 
abnormalities. The disease involves characteristic facial features and abnormalities in several 
organs including liver, heart, eye, and skeleton with additional minor involvement of the renal 
and vascular system (198). Over 94% of cases are caused by mutations in Jagged1 causing 
Jagged1 haploinsufficiency(199, 200), however, a small subset with Notch2 mutations also 
develop Alagille syndrome (201). 
 
Spondylocostal dysostosis (SD) is a rare autosomal dominant or autosomal recessive axial 
skeletal growth disorder caused by vertebral malsegmentation due to disruption of the 
segmentation clock (198, 202). Innactivating mutations in the DLL3 gene have been shown to 
cause autosomal recessive form of SD (60), where the normal function of Dll3 is to inhibit 
canonical Notch signaling by cis-inhibition in the cis-Golgi (113). Furthermore, Lunatic Fringe 
has been observed to cause similar clinical manifestations as loss of DLL3 (202-204). 
 
 
Notch(in(cancer(
 
Deregulated Notch signaling is associated with a number of different forms of cancer, conferring 
both solid tumors and cancers of hematopoietic origin (205). Depending on the tissue type, Notch 
and its different paralogs can have tumor promoting or tumor suppressing activities. Notch 
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deregulation is evident in many cancer forms, including lung and cervical carcinomas, 
neuroblastoma, medulloblastoma, breast cancer, prostate cancer, pancreatic and colorectal 
cancer, melanoma and different leukemias  (206). 
Notch mutations are present in many cancers both in primary tumors, as well as in established 
cancer cell lines, albeit in higher frequency in vitro (207). The most classical case is T-ALL, 
where over 50% of the cases harbor activating NOTCH1 mutations within the HD domain and/or 
the PEST motif (27). 
Notch(in(breast(cancer(
 
Breast cancer is the second most commonly occurring cancer and the fourth leading cause of  
cancer deaths in the world, according to the GLOBOCAN study done in 2012 by The World 
Health Organization (208). Despite being a heterogenous disease, breast cancer is molecularly 
classified into 5 major subtypes, based on estrogen receptor, progesterone receptor, and HER2-
receptor status. These five subtypes are: Luminal A, Luminal B, HER2+, Basal-like, and 
Claudin-low (209, 210). The claudin-low subtype, which is characterized by decreased 
expression of the tight-junction protein Claudin (211), exibits more heterogenous, and mixed 
features compared to the other four classical subtypes, and is thus hard to classify into any 
previously existing subtype (210, 212).   
 
 
 
Figure 3. The molecular subtypes of breast cancer.  The five subtypes are Luminal A, 
Luminal B, HER2+, Basal-like, and Claudin-low. Adapted from Prat and Perou 2009, and 
Sandhu et al. 2010. 
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The first data describing the oncogenic potential of Notch in solid tumors came from animal 
studies aimed at characterizing the “int3” insertion site of the mouse mammary tumor virus 
(MMTV) (28). This site was later identified as the Notch4 locus (213), and MMTV insertion was 
shown to drive expression of an extracellularly truncated Notch4 transcript (214). Despite not 
being essential for embryogenesis, and having a limited role in normal mammary development 
(215-217), overexpressed Notch4 promotes breast tumorigenesis by signaling upstream of c-kit 
and PDGFR (218). The MMTV also places genomic insertions in the Notch1 locus, although 
with lower frequency, which lead to the expression of similar extracellularly truncated transcripts 
as with Notch4 (219, 220). 
Notch1 has to date been intensively studied within the breast cancer field and overactivation not 
only correlates with highly aggressive forms of the disease, but has also been found to crosstalk 
with a large number of oncogenic signaling pathways (121, 221). In Ras-positive tumors Notch1 
has been identified as a downstream effector of Ras (222), while oncoproteins such as c-myc and 
Notch4 have been established as direct target genes of Notch1 (219, 222-224). Also, in ~50% of 
breast cancer cases Notch deregulation is linked with the loss or silencing of the Notch antagonist 
Numb (221, 225). Overall, high levels of NOTCH1 and JAGGED1 lead to poor survival in breast 
cancer patients (226). The most aggressive basal (triple-negative) type of breast cancer also often 
possess a specific Notch1 genetic signature (226, 227), which can include gene arrangements and 
fusions generating a gain of function in Notch1 (228). Notch1 has also been shown to drive 
migration and invasion by inducing epithelial-to-mesenchymal transition (EMT) via Slug and 
subsequent repression of E-cadherin(123, 229), as well as by regulation of extracellular matrix 
metalloproteinases (230). 
The effects of estradiol on Notch activity are conflicting. Estradiol has been reported to increase 
Notch1 protein levels while reducing transcriptional activity and nuclear localization! (231) 
Another study shows increased Notch1 activity in response to estradiol (232). On the other hand 
reduction of estrogen receptor (ER) or ErbB2 activity, notably by tamoxifen or trastuzumab 
respectively, yields elevated Notch1 signaling activity (231). 
Notch2 has in several studies been identified with tumor suppressing potential. Better patient 
survival is linked with high Notch2 expression in breast cancer (233), while ectopic activation of 
Notch2 has been linked to increases apoptosis in MDA-MB-231 breast cancer (234). Notch3 
upregulation in mammary glands has been shown to lead to the formation of mammary tumors in 
vivo (235), and Notch3 is a important driver of proliferation in ErbB2-negative breast cancer cell 
lines eg. MCF-7 (236). However, Notch3 has recently been observed to have tumor suppressing 
functions when introduced into Notch3-null breast cancer cell lines (237). In this context Notch3 
was able to induce senescence via the cell cycle inhibitor p21 (237).  
Overall, Notch1 and Notch4 as well as Jagged1 are reported to be oncogenic, while Notch2 has a 
tumor suppressive function in breast cancer (238). Notch3 appears to have context-dependent 
roles as oncogenic and as tumor suppressive (237). Upregulated Notch is also connected to the 
appearance of cancer stem cells in breast cancer (239). 
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Notch(in(prostate(cancer(
 
Both Notch1 and Jagged1 have been linked to prostate cancer growth, migration, and invasion  
via the downstream effectors Akt, mTOR, and NF-κB (240-243), with prostate cancer frequently 
metastasizing to the bone and lymph nodes (244). Many in vitro cultured prostate cancer cell 
lines exist with different Notch signatures, however, the exact expression signatures are still 
unclear. Well known prostate cancer cell lines like PC-3 and LNCaP have previously both been 
confirmed to express high Notch1, Notch2, and Jagged1, Jagged2 levels (244). However, the 
expression status of Notch3 remains unclear with some studies observing the loss of Notch3 
(244), while others report Notch3-positivity in PC-3 cells (245). Notch3 has even been found to 
be activated by hypoxia in LNCaP cells (246). 
 
Notch(and(cancer(metastasis(
 
Notch is one of many well documented inducers of epithelial-to-mesenchymal transition (EMT), 
a process indispensable in such embryonic processes as gastrulation, as well as in adult tissue 
repair requiring cell motility (247). Similarly in the cancer setting, a plethora of signaling 
pathways, including Notch, can drive EMT subsequently leading to tumor progression and 
metastasis. Notch is observed to induce metastasis via Slug-mediated repression of E-cadherin 
(123, 229) and via Snail-1! (122). Furthermore, Notch has been found to regulate extracellular 
matrix metalloproteases (230). Feedforward amplification has also been documented where 
activation of the EMT-inducer ZEB1, leads to increased Notch signaling (248).   
 
NonEcanonical(Notch(in(cancer(
 
Many signaling crosstalks have already been identified which may mediate non-canonical Notch 
in cancer (179). In breast cancer, non-canonical Notch1 has been shown to regulate Il-6 via 
IKKα/β and p53 (249), while in ovarian cancer Notch1 helps drive migration and invasiveness 
via upregulation of  lysyl oxidase (122). Also non-canonical Notch4 signaling has been 
implicated in formation of mammary tumors (250). On the other hand, non-canonical Notch3 has 
been suggested to drive cancer via the NF-κB pathway in leukemia (251). 
 
Cancer(metabolism(
 
Metabolic reprogramming is today considered a key event in the development of cancer. The 
term aerobic glycolysis was coined in the 1920s by Otto Warburg when he observed that cancer 
cells, despite access to an ample oxygen supply, preferentially metabolize glucose through the 
fermentation-like process involving purely glycolysis. This process, now known as The Warburg 
Effect, in order to be complete also involves conversion of the pyruvate to lactate and the export 
of lactate from the cell. The classic hallmarks of cancer have been previously defined (252-254) 
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and today metabolic reprogramming is considered one of the necessities of cancer development 
and maintenance. The reasons for a cancer cell to utilize aerobic glycolysis are multifaceted. 
Firstly, glycolysis on its own is a simple reaction with seemingly straightforward kinetics 
compared to a combined oxidative phosphorylation. Thus aerobic glycolysis in an environment 
with ample supply of glucose can be even faster than complete oxidation through the electron 
transport chain. Secondly, the cancer phenotype is a proliferating phenotype, which means that 
anabolic biosynthetic pathways are upregulated. This also affects the function of the citric acid 
cycle, which through cataplerosis loses many of its intermediates for biosynthesis of membrane 
lipids and nucleic acids. Other advantages include avoidance of the mitochondrial intrinsic 
apoptotic pathway and lowered ROS levels, invasion of nearby tissue with the help of the acidic 
byproduct lactate, and priming of certain tumors for survival in hypoxic niches within the 
heterogenic tumor. 
The molecular mechanisms controlling the metabolic switch, which is linked to tumor growth 
and progression, are still poorly understood. Defects in OXPHOS have been implicated in the 
Warburg phenotype but recent evidence suggests that oncogenic activation and loss of tumor 
suppressors are also critical modulators of tumor metabolism. Activation of the PI3K//Akt 
pathway, Ras, Src, Myc and loss of p53 induce glycolytic phenotypes similar to that observed by 
Warburg (255). According to Warburg’s original theory, permanent mitochondrial damage was 
the cause of upregulated glycolysis, however, more recently it has been shown that tumor 
mitochondria do respire, although with lower efficacy. The reserve capacity for OXPHOS 
observed in cancers suggests that glycolysis is preferred to support cell growth and not to 
compensate for faulty mitochondria. 
 
Notch(interacting(partners(in(cancer(
 
PI3K/Akt(
 
Akt (Also known as protein kinase B, or PKB) is a cytoplasmic serine/threonine kinase family, 
consisting of three closely related isoforms, namely Akt1-3. The Akt paralogs exhibit functional 
redundancy but also have both tissue specific and organelle specific localization and function 
(256). The Akt pathway functions as a nexus connecting extracellular signals to generate diverse 
intracellular outcomes and is the second most frequently mutated signaling pathway in cancer 
(257). In breast cancer alone, Akt mutations are observed in over 70% of cases (257). 
The PI3K/Akt pathway influences many cellular processes involved in carcinogenesis including 
proliferation, angiogenesis, and EMT (258). Akt is activated by a class of intracellular lipid 
kinases called the phosphatidylinositol 3-kinase (PI3K). PI3K is in turn classically activated by 
growth factor receptor tyrosine kinases (RTKs) such as insulin receptor (IR), insulin like growth 
factor receptor (IGF-R), epidermal growth factor receptor (EGFR), and platelet derived growth 
factor receptor (PDGFR), as well as G-coupled receptors such as Ras. PI3K phosphorylates 
phosphatidylinositol 4,5-diphosphate (PIP2) to generate phosphatidylinositol 3,4,5-triphosphate 
(PIP3) which can then bind the pleckstrin homology (PH) domains of both 3-phosphoinositide-
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dependent kinase 1 (PDK1) and Akt. This leads to PDK1 autophosphorylating itself and 
transphosphorylating Akt, making it active. The generation of PIP3 is counter-balanced by 
phosphatase and tensin homologue deleted on chromosome ten (PTEN), a phosphatase that 
reverses the action of PI3K. Also other kinases have been reported to activate Akt (257). 
Notch regulates PI3K/Akt signaling. Activated Notch1 has been observed to inhibit apoptosis by 
stimulation of anti-apoptotic proteins via a Notch1-p56lck-PI3K-Akt pathway in T cells (259). 
Similar regulation of Akt by Notch1, as well as a reciprocal relationship between the two 
proteins has been seen in T-ALL (260, 261). Downregulation of Notch1 and Jagged1 in prostate 
cancer has been detected to inhibit cancer growth and survival, as well as to induce apoptosis via 
inactivation of Akt, mTOR, NF-κB, and FoxM1 (242, 262). Notch has also been shown to 
prevent apoptosis in breast epithelial cells by induction of Akt (263). 
PTEN expression is negatively regulated by Hes1 and mutational loss of PTEN has been 
observed to induce resistance to Notch-inhibition in T-cell leukemia, giving rise to what 
Palomero et al. describe as a “shift in oncogene addiction” from Notch to PI3K/Akt subsequently 
leading to PI3K inhibitor sensitization GSI resistance (264, 265). !!
HIF(
 
The most valuable commodity in the body is the energy packed molecule ATP, which functions 
as the universal fuel and currency for travel, transport, construction, and any other type of 
activity within the mammalian organism. 
In normal oxygen conditions, or normoxia, our bodies utilize aerobic metabolism to generate 
energy in the form of ATP. Aerobic metabolism involves the mitochondria, oxidative 
phosphorylation, and the electron transport chain, where oxygen functions as an electron 
acceptor in a reaction yielding water and 32 molecules of ATP per glucose molecule. This is 
where our fundamental need for a heart pumping oxygenated blood comes from. However, 
during certain physiological conditions, such as exercise or high altitudes, or during pathological 
conditions like stroke or myocardial infarction oxygen levels may become reduced. A reduced 
oxygen environment is defined as hypoxic when O2 levels drop below 2%. In human tissues 
oxygen levels range from 2-9% while normoxic atmospheric oxygen levels are around 21% 
(266). During low oxygen supply a new set of rules apply to metabolism, called anaerobic 
glycolysis. During hypoxia, pyruvate is directly reduced to lactate in a seemingly inefficient 
reaction yielding 2 molecules of ATP per glucose molecule. The fifteen-fold decrease in ATP 
synthesis efficiency is an inevitable adaptation to low oxygen envionments, the presence of 
which is constantly monitored by the organism. In the 1950s, radiation oncologists were the first 
ones to describe tumor hypoxia, in conjunction with failed radiation therapy treatments of solid 
tumors. However, the machinery for oxygen sensing was not identified until the 1990s (267). 
Hypoxia inducible factors (HIFs) are the central regulators of oxygen-dependent gene 
expression, which is an essential part of normal cell and tissue functioning, as well as cancer 
biology. HIFs are heterodimeric proteins consisting of 3 constantly transcribed and translated, 
oxygen-labile alpha subunits (HIF1-3α), and 3 stably expressed beta subunits (HIF1-3β) (268)!
(269). Under normoxic conditions the oxygen-labile subunits are hydroxylated at specific prolyl 
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residues resulting in subsequent ubiquitination and proteasomal degradation of the α subunit by 
the 26S proteasome (270). The ubiquitination event is mediated by the von Hippel-Lindau (VHL) 
tumor suppressor protein, which via direct association to the α subunit recruits a E3 ubiquitin 
ligase protein complex (271). Beyond being regulated at the level of protein stability, HIF1-2α 
are also regulated by FIH1 by hydroxylation of the C-terminal transactivation domain of the 
HIFs leading to repression of HIF transactivation activity (272, 273). 
 
HIF1 is ubiquitously expressed in all tissues, HIF2 in select cell types and tissues, including 
endothelial cells, glial cells, kidneys, heart, lungs, and small intestine (269, 274), and HIF3 in the 
Purkinje cells of the cerebellum and corneal epithelium in the eye, as well as in tissues of the 
thymus, lung, heart, kidney, and liver (274, 275). The role of HIF3α remains largely unknown, 
although it has been observed to function as a negative regulator of HIF-mediated gene 
expression (275). Over a hundred downstream target genes of HIFs have been identified, 
however, the targets vary with HIF1 exclusively targeting glycolytic enzymes, as well as 
erythropoietin, while HIF2 activates c-myc, TGFα, lysyl oxidase, Oct4 and Cyclin D1 (276)!
(274, 277). HIF1 and HIF2 also exhibit redundancy in the control of several downstream genes, 
eg. VEGF (Vascular endothelial growth factor), and may also have contrasting function (276, 
277). Furthermore, HIF1α has been shown to functionally interact with NICD during hypoxia 
thereby increasing Notch target gene expression (278). 
 
P53(
 
The p53 tumor suppressor is the most frequently mutated pathway in cancer and a complex cross 
talk between Notch and p53 has been observed. In breast and prostate cancer p53 has been shown 
to correlate with Notch1 expression (279). Notch1 is a known target gene of p53 (280), and 
furthermore p53 is known to associate with the Notch1 transcriptional complex (NTC) in a 
MAML-dependent manner thus inhibiting Notch1-dependent transcription (172). Furthermore, 
p53 has been reported to associate with CSL within the NTC (281). Numb is able to via 
p53/MDM2 regulate Notch-levels (172) but there are also reports of direct MDM2 ubiquitination 
of Notch1 and subsequent augmentation of Notch1 activity (282). 
Likewise p63 and p73, which are part of the p53-gene family, have been reported to induce 
Jagged1 and Jagged2 thus mediating crosstalk with the Notch family during development (283). 
 
Pim(
 
The Pim-kinase family of small molecule Serine/Threonine kinases was first identified in the 
1980s when the kinase coding DNA sequence was found to be the proviral integration site of the 
Moloney murine leukemia virus.  The Pim family has 3 isoforms: Pim1, Pim2, and Pim3, which 
are ubiquitously expressed, constitutively active synergizing oncogenes regulated at the 
transcriptional, translational, and proteasomal level with short half-lives (<5 min) (284). The Pim 
genes also contain multiple transcription initiation sites giving rise to alternative splice forms. 
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The Pim kinases contain over 35 potential recognition sites for other kinases suggesting that Pim 
is under significant upstream regulation from as of yet unconfirmed phosphorylation events 
(284). 
Pim1 is expressed as both the 33kDa and 44kDa isoforms with distinct cellular localization, 
where the 44kDa contains an N-terminal proline motif which binds to the SH3 domain of ETK 
on the cell membrane (285). Pim1 is significantly protected from degradation by Hsp90, while 
association of Pim1 with Hsp70 leads to degradation (286)!(287). Pim2 is expressed as 3 splice 
isoforms while Pim3 only has a single protein-yielding transcript. The Pim proteins exhibit 61-
71% sequence homology amongst each other but show different tissue distribution.  Pim1 is 
expressed at the highest level in hematopoietic cells and in a number of solid tumors, Pim2 in 
brain and lymphoid tissue, and Pim3 in kidney, breast, and brain (288-291). 
Pim genes are generally induced by transcription factors, such as Jak/STAT and NF-κB involved 
in growth factor signaling pathways, such as intereferon-α and interleukins (292, 293). Also 
hypoxia (294-296) and Krüppel like factor 5 (KLF-5) (297) have been observed to induce Pim. 
However, deficiency in Pim kinases leads to very mild phenotypes, including a reduction in body 
size and an impaired hematopoietic growth factor response (291). Despite the lack of a profound 
phenotype, Pim kinases are important and show paralog redundancy during development and 
adult life.   
All three Pim kinases have been identified as potent oncogenes and drivers of tumorigenesis in 
both tissue culture and animal models (298). Similarly its been documented that all Pim paralogs 
associate and can cooperate with C-myc and N-myc to induce leukemias and lymphomas (298-
300). Pim kinases also function as inhibitors of apoptosis via phosphorylation and blocking of the 
pro-apoptotic BAD protein (301-304). 
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Outline(and(aims(of(the(thesis(
 
The collective aim of this thesis has been to study Notch and its interacting partners in cancer, as 
well as the role of Notch in regulation of cancer metabolism. “When Notch and Pim Unite” 
deciphers the role of PIM kinases in regulation of Notch signaling output of breast and prostate 
cancer cells and the subsequent impact on tumorigenesis. “A Metabolic Turn of Events” delves 
into the intricacies of Notch-mediated regulation of cancer cell metabolism. “Systematic KOs” 
unravels the consequences of CSL-knockout in cancer, while “Falling Into Hypoxity” deciphers 
the Notch-HIF2α crosstalk axis. 
Key(aims:(
 
• Analyze Pim kinase modulation of Notch activity in breast and prostate cancer 
 
• Analyze the influence of Notch on the metabolic state of breast cancer cells 
 
• Analyze the effect of CSL knock-out on tumor growth in breast cancer 
 
• Study the Notch and HIF2α interaction in medulloblastoma and breast cancer 
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Results(and(discussion(
 
I. When(Notch(and(Pim(Unite:(Phosphorylation/of/Notch1/by/Pim/kinases/promotes/
oncogenic/signaling/in/breast/and/prostate/cancer/cells(
 
Post-translational modification (PTM) of Notch is an emerging field in Notch-research 
attempting to explain the pleiotrophism of Notch output.  A review of the existing evidence of 
Notch PTMs can be found in Andersson et al. 2011 (30).   
 
In paper I, we started by screening cancer cells for both Notch1 and Pim1 expression. Both the 
breast cancer cell line MCF-7 and the prostate cancer cell line PC-3 exhibited robust levels of 
Notch1 and Pim1 protein. Subsequently, we wanted to know if the endogenous Notch1 and Pim1 
colocalize in these cell lines. Thus, we performed colocalization microscopy, and proximity-
ligation assays in MCF-7 cells to find out that these proteins did indeed interact. Fluorescence-
lifetime imaging (FLIM) with ectopically expressed Notch1 and Pim1 also showed physical 
interaction in PC-3 cells.  
Next, we proceeded with measuring Notch activation using the 12xCSL luciferase reporter when 
inhibiting or transiently overexpressing Pim kinases. The specific Pim inhibitor 1,10-
dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde (DHPCC-9) has previously been shown to 
inhibit all 3 Pim isoforms in vitro by binding specifically to the ATP binding site (305, 306). In a 
MCF-7 breast cancer background we found that inhibiting Pim kinases with DHPCC-9 lowered 
endogenous Notch activity in the 12xCSL luciferase assay, while overexpression of Pim1 yielded 
augmented Notch activation. Similarly, inhibiting Pim kinases in a Notch1 ectopically 
overexpressed background lowered Notch activation. To confirm that the effects were Pim kinase 
specific, Notch activity was measured using the 12xCSL luciferase reporter assay in combination 
with siRNA silencing of Pim1,2,3. 
To answer the ultimate question whether Pim kinases can phosphorylate Notch intracellular 
domains we performed in vitro kinase assays with 32-P-linked ATP. Bioinformatic sequence 
alignment of N1ICD with the consensus sequence for Pim kinases had revealed 2 potential 
phosphorylation sites for Pim on N1ICD. All 3 Pim isoforms were found to phosphorylate 
murine N1ICD and N3ICD but not N2ICD, and subsequent, mass spectrometric analysis 
performed on in vitro phosphorylated N1ICD identified Serine 2152 as the phosphorylation site. 
For N3ICD, sequence analysis and mutagenesis of 2 potential phosphorylation sites revealed 
serine 1673 to be phosphorylated. In human Notch proteins the sequence of interest was highly 
conserved and the phosphorylation sites were mapped at S2162 for Notch1 and S1672 for 
Notch3. Bioinformatic study of human N1ICD sequence and domain structure revealed that for 
N1ICD the phosphorylation site at S2162 was located in the PPD domain at the second NLS 
domain within the linker between the 2 clusters of a possible bipartite NLS (82). Mutation of the 
entire sequence including the two basic amino acid clusters and the linker has previously 
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revealed an increased cytoplasmic localization of N1ICD (82). However, a later study showed 
that mutational loss of the two basic amino acid clusters did not affect nuclear localization (81), 
suggesting that nuclear transport may be mediated by the linker sequence. Indeed, modulation of 
classical bipartite NLS linkers or sequences around such basic amino acid clusters have 
previously been shown to affect either the direct association of the linker to the backbone of 
Importin-α, or the conformation of the NLS allowing for binding to the minor and major groove 
of Importin-α (83, 84). Furthermore, N1ICD nuclear localization has been shown to be mediated 
by Importin-α 3, 4, and 7 (81). Likewise, phosphorylation of NICD has recently been shown to 
impact nuclear localization (135). 
However, in Drosophila the sequence around the second NLS has been redefined as the 
potentially phosphorylated domain (PPD) where the N-terminal basic sequence has been shown 
to also mediate direct binding to Su(H) (307). In mammals the PPD is not observed to bind to 
BTD of CSL, but may instead bind other regions of CSL (87).  Interestingly, the phosphorylated 
residue at S2162 in human Notch1 is in Drosophila Notch substituted for a Lysine (K) with a 
larger side chain comparable to that of a phosphorylated Serine. Thus it could be hypothesized 
that the constitutive binding of NICD to Su(H) in Drosophila is in other species a 
phosphorylation-dependent dynamic process (307). 
In Notch, both of the NLS domains are located in so called low complexity regions (LCRs) (74), 
and being nearly impossible to crystallize, these regions are often regarded as simple linkers 
between orderly domains. LCRs have recently however been proposed to function as signaling 
hubs contributing to regulatory functions of proteins (308, 309). For example, phosphorylation 
events may take advantage of target proteins disordered region interfaces (309-311).  
 
Figure 4. Notch1 is phosphorylated by Pim kinases at a distinct site on its intracellular 
domain (NICD). The phosphorylation site on N1ICD at serine 2152 is localized in the second 
nuclear localization sequence (NLS), also defined as the potentially phosphorylated domain 
(PPD). 
To dissect the specific effect of either phosphorylation event we designed and constructed 
phosphodead and phosphor-mimicking mutant plasmids by replacing the phosphorylated serine 
with alanine or glutamate (SA and SE mutants) in N1ICD. We found N1ICD-SA to both 
significantly lower nuclear localization as well as abolish Notch activation in the 12xCSL 
luciferase assay. 
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Figure 5. Pim-mediated phosphorylation of N1ICD potentiates Notch1 activity. 
Phosphorylation of N1ICD by Pim-family kinases enhances N1ICD nuclear localization and CSL 
association leading to increased Notch1 activity. Notch1 also upregulates Pim protein levels via a 
feed-forward loop. Collectively Pim and Notch1 synergize in mediating tumor growth, cell 
migration, and cancer metabolism. 
Notch has previously been identified as an EMT promoter via the induction of Snail-1 and Slug 
(122, 123, 229) as well as via regulation of matrix metalloproteases (230). We studied N1ICD 
phosphorylation in conjunction with PC-3 cell migration in a scratch wound assay. Jagged1-
mediated induction in wound healing showed dependence on N1ICD phosphorylation. Jagged1 
was able to increase wound healing in the control setting, but not in cells treated with DHPCC-9. 
Similar results were obtained with N1ICD-SA. 
As in paper II we studied glucose uptake, lactate production and mitochondrial membrane 
potential in MCF-7 cells transiently transfected with N1ICD and Pim. Pim slightly elevated 
glucose analog 2-NBDG uptake while DHPCC-9 treatment yielded a 2-fold increase in 2-NBDG 
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uptake compared to control levels. Likewise, the relative lactate production was increased when 
DHPCC-9 was used. The N1ICD-SA mutant also significantly increased glucose uptake and 
lactate production, showing that the results were mediated via phosphorylation of N1ICD. 
To ascertain the in vivo effects of the Notch-Pim crosstalk in an MCF-7 and PC-3 background we 
transplanted tumors of both cell lines onto the chicken CAM. MCF-7 cells were transplanted 
with transient transfections of N1ICD-WT, N1ICD-SA, N1ICD-SE and allowed to form tumors 
in the presence and absence of Estradiol (E2) and DHPCC-9. MCF-7 is an estrogen-dependent 
breast cancer cell line (312, 313), and furthermore Pim1 has been shown to be a ERα target gene 
(314). In the CAM model with MCF-7 breast cancer and in the presence of E2, N1ICD-WT and 
N1ICD- SE exhibited increased tumor formation in comparison to N1ICD-SA, and DHPCC-9 
attenuated tumor growth in N1ICD-WT tumors. In all cases N1ICD-SA lowered tumorigenesis.  
In addition, PC-3 CAM tumor xenographs were treated with increasing dose of DHPCC-9 in 
combination with DAPT. A significant combinatorial effect was observed with DAPT and 
DHPCC-9 treatments suggesting a potential new vista for combinatorial therapy for certain 
cancer forms in the future. Taken together this paper reveals a novel post-translational 
modification of Notch1 mediated by Pim kinases which potentiates Notch1-mediated 
protumorigenic effects.  
II. A(Metabolic(Turn(of(Events:(Hypo;/and/hyperactivated/Notch/signaling/induce/a/
glycolytic/switch/through/distinct/mechanisms(
 
The hallmarks of cancer proposed by Hanahan and Weinberg (252, 253)  represent a set of perks 
acquired during carcinogenesis. The transition from a healthy cell to a neoplastic state involves 
that the cell acquires a succession of these capabilities giving diverse advantages in cell 
production and survival. As discussed above, Otto Warburg had in the 1920s discovered that 
despite an ample oxygen supply cancer cells would still prefer utilizing what he termed “aerobic 
glycolysis” to meet the energy demands of the cancer cells. Today metabolic reprogramming is 
considered an emerging hallmark of cancer (253, 254) 
In paper II we wanted to decipher the impact of the Notch signaling pathway on breast cancer 
metabolism. It is known that different cancers utilize varied levels of glycolysis (255, 315).  
When comparing the estrogen-dependent MCF-7 and the triple-negative MDA-MB-231 claudin-
low breast cancer, their glycolytic phenotypes correlate with their Notch1 expression levels. 
MCF-7 cells exhibit a low glycolytic phenotype with low Notch1 levels whereas MDA-MB-231 
is highly glycolytic with high Notch1 levels.  
To answer the question whether Notch could influence the glycolytic phenotype in cancer we 
designed 3 stable GFP-tagged MCF-7 cell lines expressing different levels of Notch, in an 
attempt to either boost or lower the glycolytic phenotype in combination with elevated or 
inhibited levels of Notch. 12xCSL luciferase reporter assay confirmed that MCF-7 N1ICD-GFP 
had high Notch1 levels, MCF-7 GFP normal levels, and MCF-7 dnCSL expressed a dominant 
negative form of CSL yielding a blocked Notch phenotype. These are subsequently referred to as 
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highNotch, normalNotch, and lowNotch cells. 
The 3 stable cell lines were orthotopically xenografted into the fat pad of athymic nude mice and 
allowed to form tumors for a specific length of time after which the tumors were weighed and 
analysed by immunohistochemistry (IHC), aswell as with 18F-FDG PET. After 8 weeks highNotch 
cells had formed significantly bigger tumors than the normalNotch controls, however lowNotch cells 
had regressed. The growth of highNotch tumors was also visible in the H&E and Ki67 stainings 
showing invasive highly proliferative tumor morphology compared to control. 18F-FDG PET 
experiments showed after 5 weeks an increased 18F-FDG uptake not only in the hyperactive 
Notch tumors, but also in the hypoactive Notch tumors. A similar effect was seen in vitro with 
the stable Notch cells when glucose uptake was normalized to ATP production. By activating 
naive MCF-7 cells with immobilized FC-Jagged ligands a matching increase in glucose 
consumption was evident. Similarly by inhibiting Notch in the highly glycolytic MDA-MB-231 
cells the glycolytic phenotype as well as lactate production was reduced. To corroborate our 
findings we compared expression of the glucose transporter GLUT1, a marker of glycolytic 
cancers, with N1ICD expression in patient samples of basal versus non-basal breast cancers. A 
positive correlation was seen between N1ICD and GLUT1 expression. 
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Figure 6. Notch modulation gives rise to phenotypical changes in MCF-7 breast cancer 
metabolism.  Endogenous levels of Notch activity exhibit a normal MCF-7 cell-type specific 
cellular metabolism. Overexpression of Notch1 shifts cell metabolism towards glycolysis while 
still retaining active oxidative phosphorylation (OXPHOS). Inhibiting Notch with dominant 
negative CSL (dnCSL) leads to a complete switch to glycolysis and minimal OXPHOS activity. 
 
We next studied the downstream mechanisms of how Notch signaling could mediate changes in 
glycolytic phenotype. In highNotch cells the levels of phosphorylated Akt S473 were increased in 
similar fashion as previously reported (259-263) and the induced glycolytic phenotype could be 
rescued with the addition of the PI3K inhibitor LY294002. The highNotch cells also exhibited 
increased mRNA expression of HK2, GLUT1, ALDOA, and PDK2.  
The lowNotch cells only showed an increase in PDK2 mRNA. The lowNotch cells, however, 
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exhibited a glycolytic phenotype different from that seen in highNotch cells involving increased 
mitochondrial membrane potential and sensitivity to complex I, and V (ATPase) inhibition with 
Rotenone and Oligomycin respectively, suggesting an electron transport chain defect. Similarly 
in naïve MCF-7 cells DAPT treatment increased mitochondrial membrane potential as well as 
sensitized the cells for Oligomycin. Functional assays of complex I and IV showed decreased 
activity in lowNotch cells, and lowered complex IV activity correlated with lowered complex IV, 
and COXII, a subunit of complex IV protein levels. Not surprisingly, oxygen consumption and 
ATP production was lower in lowNotch cells, despite the ATPase still maintaining a functional 
ATP hydrolysis, excluding any functional error in complex V. When comparing lactate 
accumulation with oxygen consumption both highNotch and lowNotch cells showed a higher 
dependency on glycolysis. The lowNotch cells also showed a higher sensitivity for glucose 
deprivation further supporting the notion of glucose addiction. Finally p53 protein levels were 
found to correlate with Notch levels, and lowNotch cells were significantly destitute of p53 
protein, as also previously reported (279). Introducing wild-type p53 into lowNotch cells rescued 
the glycolytic dependence. 
Drosophila Notch has earlier been observed to be required for proper functioning of the electron 
transport chain, specifically the activity of NADH oxidase and NADH dehydrogenase. (316). 
Furthermore, Notch has been shown to control the expression of flavoproteins linked to the 
activity of the respiratory chain (317). Similarly, a patient with CADASIL (Cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy), caused by mutations 
in Notch3, exhibited mitochondrial impairment (318). Oddly, full-length Notch has also been 
reported localized to the outer mitochondrial membrane in conjunction with PINK1 (180), further 
strengthening  the case for Notch in regulation of mitochondrial metabolism.   
More recently, metabolic reprogramming has been linked to therapy resistance in another Notch-
driven tumor type namely T-ALL. T-ALLs exhibiting activating NOTCH1 mutations have been 
observed to rely on glutaminolysis for anaplerosis, and combined Notch and glutaminolysis 
inhibition shown to attenuate growth of primary T-ALL xenographs (124). However, GSI 
resistance is often observed in T-ALL and one of the metabolic escapes is the loss of PTEN and 
constitutive activation of PI3K/Akt (124, 319). 
III. Systematic(KOs:(Loss/of/CSL/unlocks/a/hypoxic/response/and/enhanced/tumor/
growth/potential/in/breast/cancer/cells/!
 
Canonical signaling from the entire family of Notch receptors is transmitted through the DNA-
binding protein CSL. However, despite functioning as an effector of NICD-mediated gene 
output, in the absence of NICD, CSL effectively quenches all Notch target gene expression. 
Phenotypical changes at the event of CSL removal have thus been hard to predict. However, 
recent research has demonstrated formation of keratinocyte tumors and mesenchymal field 
cancerization (320) in different layers of the skin at the event of CSL removal (281, 321). Loss of 
CSL has also been observed to drive the transition from normal fibroblasts to cancer-associated 
fibroblasts (CAF) resulting in cellular senescence. Simultaneous loss of p53 however, has been 
!!
!
Results(and(discussion(
!
! !
40!
shown to engage unimpeded expansion of the CSL-deficient CAF cells (281). In breast cancer, 
loss of CSL, either via shRNA or genetic ablation (322), has been reported to increase 
tumorigenicity (323). Furthemore, 33% of invasive breast carcinomas inherently exhibit CSL 
depletion (323). 
 
In paper III, we studied the effects of genetical removal of CSL in the breast cancer setting using 
CRISPR/Cas9 technology. A Cas9-induced double-strand break within the CSL locus and 
subsequent Non-Homologous End Joining (NHEJ), allowed a 1bp insertion to disrupt the reading 
frame of the CSL transcript in MDA-MB-231 cells. These cells that endogenously express high 
levels of Notch, were thus engineered to become a CSL-deficient MDA-MB-231 CSL-/- 
genotype. Two clones were selected for further studies. The MDA-MB-231 CSL-/- cells 
expressed no detectable CSL protein and showed no activation of downstream Notch 12xCSL 
luciferase reporter constructs. After transplantation into mouse mammary fat pad, as well as onto 
CAM of fertilized chicken eggs, tumor growth was analyzed. In both cases the MDA-MB-231 
CSL-/- cells formed larger tumors compared to the control MDA-MB-231 WT cells. In the mice 
xenographs MDA-MB-231 CSL-/- clones exhibited a 2.8 fold increase in tumor mass compared 
to WT already after 5 weeks. Histological analysis of mouse tumors revealed that MDA-MB-231 
CSL-/- were more proliferative by Ki67 staining. Similarly proliferation was increased in MDA-
MB-231 CSL-/- cells in vitro as analyzed by EdU staining. Apoptosis was inhibited in MDA-MB-
231 CSL-/- cells as assayed by measurement of cleaved Caspase-3. In a transwell migration assay 
clone #1 showed enhanced migration whereas clone#2 did not. However, both clones showed 
more aggressive invasive properties in a Matrigel-coated transwell invasion assay.  In 
conclusion, removal of both alleles of the CSL gene yielded enhanced tumor growth in vivo and 
increased invasiveness in vitro.  
 
The MDA-MB-231 CSL-/-  cells also exhibited a multinucleated giant-cell phenotype suggestive 
of a mitosis defect. This phenotype was characterized by cells having a large volume with either 
a giant nucleus or a polyploid nucleus, with the large cells often surrounded by smaller cells. 
Single cell analysis revealed that the cells indeed presented with aberrant mitosis, where parent 
cells divided into multiple daughter cells or exited mitosis without cytokinesis, suggesting that 
loss of CSL may affect mitotic progression. 
 
To study the molecular mechanisms downstream of CSL derepression, we analyzed the hypoxic 
response, and specifically the HIF1α levels. Hypoxia is a known driver of aggressive metastatic 
cancer (324), with HIF1α having well documented interactions with the Notch pathway (122, 
150, 273, 278). Loss of CSL yielded increased levels of HIF1α in normoxia, which resulted from 
stabilization and increased half-life of the HIF1α protein. HIF1α mRNA levels remained 
unchanged between MDA-MB-231 WT and MDA-MB-231 CSL-/- cells. Increased HIF1α in 
MDA-MB-231 CSL-/- cells was also accompanied by hypoxic downstream gene upregulation, 
although with a different signature between the two clones. Clone #1 upregulated VEGF-A gene 
expression while clone#2 elevated the expression of STC2 and KLF8. 
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Ultimately, we wanted to assess the transcriptional signature of CSL-deficiency. By culturing 
MDA-MB-231 WT cells in vitro on immobilized Jagged1 ligands, and using the γ-secretase 
inhibitor DAPT to quench Notch cleavage, we were able to define the Notch transcriptional 
signature that was both ligand and γ-secretase-dependent. Subsequent RNA-sequencing analysis 
revealed this to contain 139 genes, including well-established Notch downstream targets, such as 
HES1, HES4, and NRARP. On the other hand, transcriptomic analysis of MDA-MB-231 CSL-/- 
cells revealed 1768 genes that were upregulated, and comparison between the 1768 genes and the 
139 genes in the Notch signature revealed only 47 genes common in both categories. To analyze 
in vivo transcriptome we utilized the S3-technology (325) to bioinformatically sort out the 
human mRNAs from the tumor-stroma mixture and observed similar distinct transcriptomes in 
vivo as in the in vitro situation between the MDA-MB-231 WT and MDA-MB-231 CSL-/- 
tumors. Overall, the data suggest that CSL transcriptionally controls a number of genes not part 
of the canonical Notch signature. 
 
IV. Falling(into(Hypoxity:(Notch/signaling/upregulates/HIF2α/expression/in/tumor/cells(
 
The hypoxia machinery is known to interact with the Notch pathway with HIF1α stabilizing 
NICD in the canonical pathway (278), and FIH1 acting as a negative regulator of both  HIF1α 
and NICD (150, 273).  Evidence also exists that NICD can non-canonically stabilize and 
augment the effects of HIF1α (122). 
In paper IV we set out to study if the canonical Notch pathway is capable of regulating another 
HIF paralog, namely HIF2α. Indeed, already in normoxia we observed increased HIF2α mRNA 
expression when Notch was activated in eight different cancer cell lines (derived from brain, 
blood, lung, breast, and renal cancer). Similarly an upregulation of HIF2α mRNA was evident in 
both primary glioblastoma and breast cancer cells, and in non-tumorigenic primary mesenchymal 
cells. As in normoxia, HIF2α mRNA upregulation was also evident in hypoxic conditions, and 
transcriptome analysis comparing Jagged1-mediated active Notch signaling with HIF2α 
expression correlated positively. NRARP (Notch-regulated ankyrin repeat-containing protein) 
was used as a control for active Notch-mediated transcription. 
To decipher whether nuclear NICD was required for increasing HIF2α expression we utilized a 
Notch1 ICD-Estrogen receptor fusion construct (NERT2) which is normally localized to the 
cytoplasm, but translocates to the nucleus with the addition of Tamoxifen (249). When 
transiently expressed in Tamoxifen-treated DAOY medulloblastoma cells, NERT2 induced the 
expression of HIF2α and NRARP, while simultaneous expression of a dominant negative 
MAML (dnMAML) abolished the effect, suggesting that the upregulation of HIF2α is mediated 
via canonical Notch signaling. To test whether HIF2α is a direct transcriptional target of Notch 
we tested activation with a 2kb HIF2α promoter-luciferase reporter. However, no activation of 
reporter was observed with cells cultured with Jagged1 ligand. To corroborate this, we blocked 
protein translation in combination with Notch activation, and measured mRNA of both HIF2α 
and NRARP. While NRARP was potently induced, HIF2α was not suggesting that HIF2α is not a 
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direct Notch target mediated by Notch ICD/CSL. 
The protein level of HIF2α was observed elevated already in normoxia both in primary breast 
cancer and medulloblastoma cell lines D324 and DAOY following N1ICD expression. A more 
moderate expression of Notch1 using immobilized Jagged1 did not significantly increase HIF2α 
in primary breast cancer or MDA-MB-231, suggesting dose dependency. However, both during 
hypoxia and CoCl2 treatment as a chemical mimic of hypoxia, Notch was able to induce HIF2α 
in primary breast cancer, MDA-MB-231, as well as in D324 and DAOY respectively. 
Interestingly, Notch induction also led to a prototypical HIF1α-to- HIF2α switch (326) in D324, 
primary breast cancer, and MDA-MB-231 cells. 
To compare the transcriptomes of Notch and HIF2α, we started by checking whether VEGRα 
and AREG (Amphiregulin), two genes known to be upregulated by HIF2α, were in fact induced 
by Notch. Indeed, both were upregulated by Notch and the induction was halted by DAPT. 
Following this, we extended the transcriptional screening to a genome-wide level in DAOY cells 
stably expressing NERT2 with Tamoxifen treatment under both normoxic and hypoxic 
conditions. 59 of 547 genes upregulated by Notch in hypoxia were inhibited by HIF2α siRNA 
knockdown, suggesting that circa 10% of the Notch transcriptome requires active HIF2α. 
Notch1 and Notch2 have previously been shown to have different roles in medulloblastoma 
tumors (327), however a controversy has risen from a report indicating that Notch is dispensable 
in Sonic Hedgehog-driven medulloblastomas (328). In our paper, DAOY cells were transiently 
transfected with Notch1 and Notch2 ICD and enhanced tumor growth was observed in the CAM 
tumor model only in Notch2 cells keeping with the data from Fan et al. 2004 (327). Tumor 
suppressive functions for HIF2α have previously been reported in both human breast cancer and 
rat gliomas (329, 330). When comparing NERT-DAOY and NERT-DAOY HIF2α-deficient cell 
tumors on CAM, activation of Notch1 did not induce tumor growth, however the HIF2α-
deficient tumors promoted rapid growth, suggestive of a tumor suppressive role for HIF2α also in 
this context. 
Conclusions(
 
Collectively this thesis presents six novel degrees of Notch pleiotropism in different forms of 
cancer (Figure 7). We have expanded the pool of Notch post-translational modifications to 
include Pim-mediated phosphorylation of Notch1. The synergy between Pim and Notch enables 
optimized Notch activation during tumorigenesis in both breast and prostate cancer.  We show 
that both high and low Notch can induce glycolysis and that Notch is required for functional 
oxidative phosphorylation. We expand on the metabolism saga by showing that knocking out 
CSL yields a hypoxic response via HIF1α in breast cancer thus increasing tumorigenicity. In 
medulloblastoma, however, Notch1 induces HIF2α, which exhibits tumor suppressive properties. 
Finally the knock-out of CSL in breast cancer also influences a vast population of genes 
independently of Notch. These six findings expand the Notch-verse and bring us closer to 
complete understanding of The Notch. 
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Figure 7. Six Degrees of Intracellular Turbulence.   
Future(perspectives(!
As a follow-up to the Notch-Pim interaction in paper I, we will continue to study the interaction 
between Pim and Notch by utilizing CRISPR methodology to create both knock-outs and knock-
ins of the phosphorylation site of Notch1 in both MCF-7 and PC-3 cell lines. Knock-ins will 
replace the phosphorylated serine with alanine in both N1ICD to gain endogenous insight into 
the Pim – Notch crosstalk axis. We will also widen the paradigm to include triple-negative 
MDA-MB-231 breast cancer. 
Furthermore also utilizing CRISPR, we will expand our investigations to involve Notch3 and 
decipher both the physiological and oncogenic role of Notch3 phosphorylation. For Notch3 the 
phosphorylation site has already been pinpointed to the RAM domain inside the binding groove 
between RAM and CSL, where the added phosphate interferes with binding of WxP to RAM (87, 
88). N3ICD-SA and N3ICD-SE mutants have been devised, and our data indicate that Pim-
phosphorylation inhibits the activity of N3ICD as measured by the 12xCSL luciferase assay, and 
subsequently lowers the levels of p21 in MCF7 cells. Supporting this notion is the observation 
that Notch3 has previously been identified as a tumor suppressor in breast cancer in connection 
to p21 expression (237). 
Modern day cancer treatment is evolving towards combinatorial therapy where monotherapy has 
failed due to therapy resistance or high drug dose toxicity. With several drugs targeting both 
Notch and Pim currently in clinical trials (ClinicalTrials.gov), our discovery of direct Notch-Pim 
pathway crosstalk opens up a new possible combinatorial regimen for cancers expressing high 
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levels of both Notch1 and Pim. 
Similarly our data indicate that blocking the Notch paralogs sensitizes breast cancer cells to 
glucose deprivation. 2-deoxy-D-glucose (2-DG) is a glucose analog currently in clinical trials 
which when taken up by cancer cells, competes with glucose and halts glycolysis. Thus a 
plausible combination therapy could consist of a γ-secretase inhibitor and 2-DG to treat certain 
cancers. 
The future also involves deciphering the significance of the Notch-independent genes affected by 
CSL removal. The mode of action for CSL is undergoing a paradigm shift, where newly surfaced 
data argue for Notch-mediated dynamic recruitment of CSL to target sites (103). In this model 
CSL remains only loosely, or not at all associated to DNA in the repressor-state. However, Castel 
et al. also show static binding of CSL to Notch-independent sites. Whether the Notch-
independent genes regulated by CSL-removal are separate individual genes, or if the change in 
gene expression is the result of a broader modification of the chromatin landscape remains to be 
determined. 
We have touched upon the intricacies of Notch- HIF crosstalk, yet many questions remain 
unanswered. The controversial data implicating HIF2α in both tumor suppressive and tumor 
promoting roles hint of dose-dependency. Furthermore, whether the other Notch paralogs can 
regulate HIF2α, and how HIF3α fits into the cross-talk, remain to be seen (331). 
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Article(not(included(in(thesis(
Inhibiting(Notch(activity(in(breast(cancer(stem(cells(by(glucose(functionalized(
nanoparticles(carrying(γEsecretase(inhibitors(!
The cancer stem cell (CSC) paradigm suggests that a small subset of so called cancer stem cells 
in tumors exhibit similar self-renewal potential as normal stem cells (332). This hijacking of the 
stem cell characteristics by cancer cells aids not only in tumor initiation, but also in metastasis, 
recurrence, and therapy resistance (333). Interestingly, signaling pathways involved in 
controlling self-renewal of both stem and progenitor cells, can when dysregulated contribute to 
oncogenesis (332). Thus, in concordance with the cancer stem cell model of cancer, specific 
targeting of this subpopulation should prove more effective than classical cancer therapies. One 
of the most promising new targeted CSC-therapeutics is nanoparticle drug delivery.  
 
In this paper we started off by utilizing the previously characterized highNotch, normalNotch, and 
lowNotch cells to explore the influence of Notch on breast CSC population. As previously 
reported, highNotch cells outgrew the normalNotch, and lowNotch counterparts, however, highNotch 
cells also expressed increased levels of CD44, a known marker for CSCs. To confirm the 
presence of CSCs we plated highNotch, normalNotch, and lowNotch cells on low adherence plates in 
serum free conditons with supplemental growth factors. The highNotch cells formed significantly 
higher number and bigger spheroids than normalNotch cells, whereas lowNotch cells were unable to 
form spheroids. The presence of CSCs in highNotch cells was further supported by 
xenotransplantation of 1000 cells of each cell line into nude mice, as only CSCs are capable of 
initiating cancer growth when only a small number of cells is transplanted. The highNotch cells 
formed tumors in 3/5 mice, whereas normalNotch, and lowNotch cells did not form any tumors even 
after 3 months. 
 
MCF-7 cells express the ER-receptor and are thus dependent on estrogen for optimal growth in 
vitro and in vivo. The normalNotch cells exhibited higher sensitivity for estrogen depletion 
compared to highNotch cells. Immunolabeling revealed decreased ER-receptor expression in 
highNotch compared to normalNotch cells. To further elucidate if the estrogen independence was 
linked to the CSC population, we grew tumors derived from dissociated spheroids of highNotch 
cells in gonadectomized mice and compared it to the control group where were tumors grown in 
normal mice. Expression of α6 integrin in the spheroids confirmed the CSC phenotype. Initial 
growth of tumors in gonadectomized mice was slower, reaching a comparable size to the control 
tumors only after 7 weeks. Yet, 4/6 mice transplanted with highNotch cells developed tumors also 
in gonadectomized mice. Immunohistochemistry revealed high expression of CD44, the 
proliferation marker Ki67, as well as cytokeratin 5/6, indicators of basal like cancer phenotype. 
 
Based on our previous data that highNotch cells exhibit increased glucose uptake we also wanted 
to know the metabolic phenotype of the highNotch CSCs. Indeed, after enriching for CSCs from 
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the highNotch tumors we saw increased glucose uptake with 18F-FDG PET. Similarly, spheroids 
generated from endogenous MCF-7 and MDA-MB-231 cells grown in non-adherent conditions 
also displayed increased glucose uptake compared to their adherent counterparts. Since MDA-
MB-231 cells and normally more glycolytic than MCF-7 cells, the difference between each cell 
line’s CSCs and the heterogeneous cancer cell population was more pronounced in MCF-7. In 
addition, when measuring extracellular acidification rate (ECAR, measured in milli-pH/min) in 
lowNotch and MDA-MB-231 cells using the Seahorse analyzer we observed a higher glycolytic 
reserve capacity in MDA-MB-231 compared to lowNotch cells. Cells with lower glycolytic 
reserve capacity are more dependent on glycolysis.  
 
 
Figure 8. Extracellular acidification (ECAR) profile showing results of a hypothetical 
glycolytic measurement using the Seahorse XF analyzer. Addition of 10mM glucose induces 
glycolysis in cells increasing ECAR above the level of non-glycolytic acidification. Oligomycin 
inhibits oxidative phosphorylation forcing cells to utilize their glycolytic reserve capacity. 
Addition of 2-DG inhibits glycolysis and stops cellular glycolysis. Picture adapted from 
Seahorse Bioscience glycolysis stress test profile. 
 
Since Notch signaling is required for self-renewal of CSCs and as CSCs express a glycolytic 
phenotype characterized by increased glucose uptake, we sought to target CSCs using glucose 
functionalized nanoparticles loaded with gamma-secretase inhibitors (GSI). Mesoporous silica 
nanoparticles (MSN) have been demonstrated to function well as drug deliverers in vitro (334), 
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and we have previously shown MSNs to be good deliverers of GSI with good therapeutic 
efficacy (335). In our study different conjugation methods were devised where glucose was 
attached to MSN either directly or via the polyethyleminine (PEI) linker. Particles were also 
functionalized with fluorescein isothiocyanate or with the fluorescent probe Atto647. 
Subsequently, the best uptake of particles in MDA-MB-231 cells after 4h of incubation was 
obtained with directly conjugated MSN-Gluc, and MSN-PEI-Gluc particles conjugated under 
organic conditions. Subsequent experiments were thus conducted with these particles.  
 
We next sought to analyze uptake in the CSC population. CSCs were identified using the 
aldehyde dehydrogenase-1 (ALDH1) activity. MSN-PEI-Gluc particles exhibited higher uptake 
with glucose functionalization compared to control particles lacking glcose both in cancer cells 
and CSCs. However, MSN-PEI particles were also readily taken up by cancer cells. Particle 
uptake was further examined by confocal microscopy where glucose functionalized particles 
exhibited a intracellular vesicular pattern while non-glucose functionalized particles aggregated 
at the cell border. The particle uptake was also more pronounced in MDA-MB-231 cells than 
healthy MCF-10 mammary epithelial cells. However, increased uptake in CSCs with MSN-Gluc 
was only observed in MCF-7 but not MDA-MB-231 cells. 
 
In order to verify the tumor targeting functionality of the particles in vivo, we orthotopically 
transplanted 3x106 MDA-MB-231 cells into the mammary glands of female NOD SCID mice, 
however MSN outperformed MSN-Gluc particles in uptake. The therapeutic efficacy MSN-PEI-
Gluc particles was also tested on CAM xenographs where MSN-PEI-Gluc particles were loaded 
with DAPT. Control treatment with free DAPT, as well as DAPT loaded particles reduced 
number of cancer cells per mg tissue. Similarly the the number of CSCs was also reduced in both 
DAPT and MSN-PEI-Gluc-DAPT-particle treated tumors. However, therapeutic efficacy was 
also obtained with MSN-PEI-DAPT particles. 
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Experimental(procedures(
(
12xCSL(luciferase(reporter(
 
The 12xCSL luciferase reporter, first described by Honjo et al. (336) has been utilized before 
(122) and in several of the projects presented in this thesis (337). The reporter is based on a TP-1 
promoter containing six copies of a 50-mer oligonucleotide each containing two CSL binding 
sites (338), and allows real time analysis of Notch activation (338). 
 
CRISPR/cas9(
 
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), and CRISPR 
associated (Cas) system was developed in 2013 to rival the TALEN and Zinc finger gene editing 
systems. CRISPR was originally identified in bacteria as a defense system against foreign DNA, 
either plasmid or viral. Today, three different types of bacterial CRISPR systems have been 
described, out of which type II is the one widely used in genome engineering and often simply 
referred to as CRISPR. 
The CRISPR/Cas9 system consists of 2 components, namely a guide RNA (gRNA), and an 
endonuclease, the Cas9. The gRNA is designed to contain a targeting sequence complementary 
to the genomic DNA, a scaffold sequence for Cas9, and the Protospacer Adjacent Motif (PAM) 
sequence immediately following the target sequence. The PAM signals the site for Cas9 
cleavage, generating a double-stranded break (DSB). Following the Cas9 DSB, repair can occur 
via Non Homologous End Joining (NHEJ) or Homology Directed Repair (HDR) pathway. The 
NHEJ can result in insertions or deletions in the DSB which often lead to frameshifts or 
premature stop codons. On the other hand, the HDR pathway requires the presence of a repair 
template to fix the DSB. This method can be used to introduce specific nucleotide changes. 
 
CAMEmodel(
 
The chorioallantoic membrane (CAM) model developed in 1911 by Rous & Murphy (339) is a 
multipurpose in vivo tool to study various physiological phenomenon in the developing chick 
embryo. Thanks to the highly vascularized CAM membrane, the model can be used to study 
tumor xenograph growth, response to therapy, angiogenesis, hemodynamics, immune cell 
trafficking and more. 
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Figure 9. Chorioallantoic membrane (CAM) tumor model.  MCF-7 breast cancer xenografts 
on CAM incubated in a De Rycke Savimat MG 200 egg incubator 
Proximity(ligation(assay(–(PLA(!
The proximity ligation assay (PLA) is a method allowing for detection of endogenous protein 
interactions at single-molecule resolution. Originally developed by Fredriksson et al. (340) and 
later adapted for in situ use by Söderberg et al. (341), this technique utilizes oligonucleotide 
labeled antibodies to detect protein-protein interactions only 30-40nm apart. A PLA protocol 
consists of fixing of the samples and incubating with two primary oligonucleotide labeled 
antibodies. Being bound in close proximity, the two oligonucleotides can hybridize. This leads to 
binding of two additional connector oligonucleotides, which are ligated together to form a 
spherical DNA molecule. Subsequent amplification by rolling circle amplification (RCA) leads 
to the formation of a long single stranded DNA molecule, which collapses into a bundle. Finally, 
the bundle is detectable by hybridization of fluorescently labeled complementary 
oligonucleotides (342). 
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supported me throughout my life to the point where I have felt completely spoiled. I am truly 
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